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Abstract 
 
The regulation of microRNA biogenesis by ribosome- 
 
interacting proteins 
 
 
 
Brian Frederick Pickering, Ph.D. 
 
Supervisory Professor: Dihua Yu, MD, Ph.D. 
 
MicroRNA (miRNA) are small, non-coding RNAs that affect gene expression through 
degradation of complementary mRNA targets or inhibition of translation.  As they affect 
approximately 50% of all cellular processes, miRNA are tightly regulated by the cell 
through transcriptional and post-transcriptional mechanisms.  Transcribed miRNA are 
capped and polyadenylated (referred to as pri-miRNA) which are cleaved by Drosha and 
DGCR8 to generate 60-90 nucleotide precursor miRNA.  The precursors are cleaved 
again by Dicer and loaded into the RNA-induced silencing complex (RISC) of which 
Argonaute 2 is the functional component.   Many of the proteins involved in miRNA 
biogenesis share a common role in ribosomal RNA regulation.  Here we characterize two 
ribosome-associated proteins that are important for miRNA biogenesis.  In one study, we 
identified nucleolin as a positive regulator of pri-miR-15a/miR-16-1 biogenesis.  
Nucleolin expression is inversely proportional to mature miR-15a/miR-16-1 expression.  
While nuclear localization of nucleolin increases miR-15a/16-1 expression, cytoplasmic 
localization of nucleolin decreases it in a mechanism dependent on the interaction of 
nucleolin with Drosha and DGCR8.  Furthermore, pri-miR-15a/miR-16-1 is bound by 
nucleolin, which facilitates its processing in vitro.  In another study, we analyzed TCGA 
patient datasets to uncover a miRNA signature associated with ZEB1/2 expression that 
	   vi	  
refutes current models of miR-200 family (miR-200a/b/c, miR-141, miR-429) regulation.  
In breast cancer cell lines with low miR-200 expression an abundance of primary and 
precursor species exist.  We found these precursors are able to regulate other miR-200 
family members in a coherent feedforward loop, independent of transcription, by titrating 
away a repressor complex.  We identified the repressor as Receptor of Ribosome Binding 
Protein 1 (RRBP1) by developing a new technique to capture endogenous protein-RNA 
complexes in vivo called Cross-linking and PNA Pulldown (CLaPP) assay.  RRBP1 
inversely correlates with miR-200 expression in cell lines and through gain- and loss-of-
function studies.  TGF-β treatment transcriptionally increased RRBP1 abundance 
resulting in loss of miR-200 expression.  Lastly, RRBP1 was found to directly associate 
with miR-200 precursors through iCLIP analysis. 
 In summary, the ribosome-associated proteins nucleolin and RRBP1 were 
identified and characterized as two novel proteins involved in miRNA biogenesis, each 
forming feedforward miRNA loops that regulate distinct cellular processes.      
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1. Introduction
1.1. MicroRNAs
 MicroRNAs (miRNA) are short ~21 nucleotide non-coding RNA that negatively 
affect protein expression by either degrading complementary mRNAs, inhibit mRNA 
translation, or by inhibiting initiation of the translational machinery (1).  The first miRNA 
identified was by Victor Ambros’ group when they isolated a small RNA that regulated 
lineage commitment in C. elegans (2).  Since then miRNAs have been found in higher 
eukaryotes all with similar mechanisms of regulation of and by miRNAs.  They regulate 
upwards of 50% of cellular mRNAs and every major disease studied to date has altered 
miRNA expression patterns (3).  Yet with all that we have learned about miRNAs in two 
decades of research, new insights are continually being uncovered changing paradigms of 
miRNAs function, regulation, and impact in disease and development.
1.1.1. MiRNA function
 MicroRNAs undergo multiple steps of processing before the functional mature 
miRNA is generated.  The process begins with transcription by RNA pol II generating a 5’ 
capped polyadenylated transcript referred to as a primary microRNA (pri-miRNA) (4, 5).  
While RNA pol II transcribes the majority of miRNAs there are a small fraction (~5%) that 
are transcribed by RNA pol III and which are associated with Alu repeat regions (6, 7).  
These pri-miRNA can be tens of kilobases in length.  The first step of post-transcriptional 
biogenesis is orchestrated by Drosha and DiGeorge’s Syndrome Critical Region 8 (DGCR8) 
proteins called the microprocessor complex (8, 9).  The miRNA forms a double stranded 
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hairpin structure and DGCR8 binds to the flanking ssRNA within ~30 nucleotides from the 
hairpin.  Drosha cleaves ~11 nucleotides from the junction between ssRNA and dsRNA to 
generate the 60-90 nucleotide precursor miRNA (pre-miRNA) that has a two nucleotide 3’ 
overhang (10, 11).  The pre-miRNA is exported to the cytoplasm after binding to Exportin5 
and Ran-GTP where it is recognized by Dicer that cleaves the remaining loop structure by 
measuring the distance from the two nucleotide overhang and cleaving the opposite end (12, 
13).  Argonaute 2 (Ago2) binds the double stranded RNA, which is now approximately 21 
nucleotides with two nucleotide overhangs at either end, and separates the two strands (14).  
Ago2 binds the functional strand, called the guide strand, while the complementary strand, 
called the passenger strand, is degraded.  Ago2 guides the now mature miRNA to find its 
mRNA targets dictated by an 8-nucleotide seed region in the 5’ of the miRNA that is 
complementary to target (15).  Perfect complementarity results in endolytic cleavage of the 
mRNA target while incomplete complementarity can result in stalling of the ribosome on the 
mRNA, inhibition of the ribosomal initiation complex altogether, or deadenylation and 
exonuclease degradation.
 The biogenesis pathways for miRNAs were fleshed out soon after their discovery but 
since then it has become apparent that these pathways are not linear as initially described and 
are controlled by many other regulatory factors.  
1.1.2. Transcriptional regulation of miRNAs
 MiRNAs are transcribed predominantly by RNA pol II but the genes encoding them 
can have unique gene structures.  In the simplest case miRNAs can be found as separate gene 
2
entities with their own promoter.  Changes in the activity of their transcription factor directly 
affect the generation of the pri-miRNA.  Things become a bit more complex when one 
considers that miRNA can reside within protein coding genes.  The location can either be in 
an intron or within an exon.  Intronic RNAs require the transcription factor of the host 
protein-coding gene to generate the RNA but can then be differentially spliced out to make 
the pri-miRNA.  Some intronic miRNAs can also have their own separate promoter within 
the intron allowing for transcription to occur from either the host gene promoter or their own 
promoter (16).  Exonic miRNAs are hairpins that exist within the coding region of a protein-
coding gene.  Cleavage of the hairpin often can disrupt the coding sequence negatively 
impacting the expression of host gene (17).
1.1.3. Epigenetic regulation of miRNA
 Epigenetic modification can be broadly grouped into methylation of the DNA through 
CpG islands and histone modifications.  Nearly half of all miRNA genes are associated with 
CpG islands though not all are necessarily methylated (18).  Loss of both DNA 
methyltransferases, DNMT1 and DNMT3b, in a double knockout restored only 6% miRNAs 
in HCT116 cells (19).  Treatment with 5-aza-2′-deoxycytidine (5-AzaC) increased the 
expression of only 13 miRNAs suggesting that CpG methylation may not be a dominant 
mechanism by which cells regulate miRNA expression (20).  Combining treatments to 
reverse CpG methylation along with histone deacetylase inhibition (HDACi) restored again 
restored approximately 5% of all miRNAs suggesting epigenetic modification by both DNA 
methylation and histone modifications play only a minor role in miRNA expression 
3
regulation (21).  Additionally, HDAC inhibition may in reality be regulating post-
transcriptional biogenesis by altering the acetylation of DGCR8 (22) 
1.1.4. miRNA biogenesis: the microprocessor complex
 The post-transcriptional biogenesis of miRNAs is a multi-step process involving 
multiple protein complexes in both the nucleus and the cytoplasm.  The first step of 
processing, cleavage by Drosha and DGCR8, occurs simultaneously with transcription (23).  
Drosha is the enzymatic component of the complex and cleaves miRNA via an RNase III 
domain in an endonuclease reaction.  DGCR8 is thought to stabilize the RNA to give a 
proper alignment and allow Drosha processing.  Evidence suggests that DGCR8 binds RNAs 
is a non-specific manner giving it a large repertoire of structures and sequences in which it 
can bind (24).  As the core components of miRNA processing, the cell tightly regulates the 
levels of Drosha and DGCR8.  Drosha negatively regulates the expression of DGCR8 by 
cleavage of a hairpin structure in the 5’ UTR of the DGCR8 mRNA (17, 25).  DGCR8 
stabilizes Drosha via a protein-protein interaction (17).  Therefore, increases in DGCR8 lead 
to stabilization of Drosha that in turn cleaves the mRNA of DGCR8 reducing both their 
levels.  Processing of miRNAs is not the only function of the microprocessor complex (26).  
An analysis of DGCR8-interacting RNAs demonstrated that mRNAs, snoRNAs, and 
lncRNAs are all targets of DGCR8 (27).  Similarly, not all miRNAs require the 
microprocessor complex for their expression (28). 
 Drosha and DGCR8 are subject to post-translational modifications in addition to 
expression regulation.  Drosha is phosphorylated on Ser300 and Ser302, which is necessary 
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for its nuclear localization.  Mutations at either one of these sites to alanine inhibits nuclear 
localization and decreases miRNA biogenesis (29).  DGCR8 is phosphorylated at 28 different 
residues by Erk1/2 which increases protein expression (30).  Phosphorylation does not alter 
the miRNA processing ability of DGCR8 but does stimulate a pro-growth miRNA profile in 
HeLa cells.  In addition to phosphorylation, DGCR8 can also be acetylated and deacetylation 
by HDAC1 increases mature miRNA expression (22).
1.1.5. Exportin-5/Ran-GTP
 After processing of the primary miRNA by the microprocessor the pre-miRNA is 
exported out of the nucleus by Exportin-5 and Ran-GTP in complex (12).  Exportin5, long 
thought to be a minor transporter of tRNAs, binds to the dsRNA stem of miRNA and has a 
propensity for RNAs with a protruding 3’ end such as the product from cleavage by the 
microprocessor complex (31, 32).  Exportin-5 has been shown to generate a truncated 
product due to microsatellite instability in various cancers.  The truncated mutant does not 
possess the final 22 amino acids of the protein and this causes miRNA precursors to be 
trapped in the nucleus and fail to generate mature miRNA (33). 
1.1.6. Dicer/TRBP/PACT
 Once the precursors are in the cytoplasm they are recognized by another RNase III 
enzyme, Dicer.  Dicer is a conserved protein found in single-celled eukaryotes as simple as 
Schizosaccharomyces pombe.  Interestingly, while yeast contain Dicer they do not make 
miRNAs but possess the ability to generate RNAi (34).  Dicer is a large protein at around 200 
5
kDa that cleaves the terminal loop of precursor miRNAs.  The PAZ domain binds to the 
protruding 3’ end and the distance between the catalytic RNase III domains and the PAZ (~65 
Å) determines the length of the dsRNA product at around 22 nucleotides (35, 36).
 Mice with Dicer knocked out are embryonic lethal, presumably due to depletion of 
stem cells indicating Dicer, and by extension miRNAs, are necessary for maintaining stem 
cell populations in early development of mice (37).  In ovarian cancer, patients with low 
Dicer expression were associated with poor clinical outcomes as well as chemotherapy 
resistance (38).  In that study several mutations were identified but did not correlate with 
expression data indicating other mechanisms leading to down-regulation of Dicer.  Similarly, 
decreased Dicer expression was found in breast cancer and prostate cancer patients (39, 40).  
In prostate cancer the tumors as a whole had increased Dicer expression yet metastases had 
significantly lower Dicer expression indicating hemizygous expression of Dicer may give 
tumor cells a selective advantage for metastasis.  One mechanism uncovering the regulation 
of Dicer expression was via the p53 protein family member TAp63 that serves as a 
transcriptional activator of Dicer (41).  Loss of TAp63 in patient tumors and mouse models 
resulted in lower levels of Dicer and an increased incidence of metastasis.     
 In mammals, Dicer interacts with TAR RNA-binding protein (TRBP) and PACT.  
TRBP and PACT are not necessary for miRNA processing but have positive and negative 
effects, respectively (42, 43).  Moreover, binding of either of these two proteins generates 
non-redundant altered cleavage, the product of which is referred to as isomiRs. 
Phosphorylation of TRBP by Erk increases the stability of the complex between Dicer and 
TRBP and results in increased expression of pro-growth related miRNAs (44).  TRBP not 
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only affects bindings and processing of precursors to Dicer but is necessary to exchange the 
cleaved dsRNA from Dicer to Ago2 in the formation of the RNA-induced silencing complex 
(RISC) (45).
1.1.7. Argonaute and the RISC complex
 Argonaute 2 (Ago2, also known as eukaryotic translation initiation factor 2C, 2 
(EIF2C2)) is the major constituent of the effector complex of miRNA known as RISC.  
Evidence suggests Ago2 receives the dsRNA with 5’ and 3’ overhangs from the Dicer 
complex with TRBP bound to the more thermodynamically stable end of the miRNA and 
Ago2 binding to the other end (46, 47).  The two miRNA strands are separated into the guide 
strand (functional) and the passenger strand (degraded).  Separation of the strands is due to 
the RNA helicase activity of Ago2.    Studies as to how the guide strand is selected point 
towards thermodynamic stability, specifically at the 5’ end (48, 49).  
 Ago2 works in conjunction with GW182 (also known as TNRC6) through two 
phenylalanines to recruit the Pan2-Pan3 and Ccr4-Caf1 deadenylase complexes that 
deadenylates mRNAs in a biphasic manner coupled with decapping to trigger mRNA decay 
(50).  GW182 contains several domains in the carboxy-terminus including an RNA 
Recognition Motif (RRM) and a PAM2 motif that recognizes poly(A) binding protein C 
(PABPC) that coats the poly(A) site of mRNA.  The interaction between GW182 and PABPC 
is required for both translational repression and for miRNA mediated deadenylation (51).  
 Given its importance in regulating global protein expression, it is not surprising that 
Ago2 undergoes extensive post-translational modifications.  There are seven different 
7
phosphorylation sites that have been identified.  Phosphorylation of Ser387 by p38 results in 
increased accumulation of Ago2 in P-bodies (52).  Tyrosine phosphorylation at Tyr529 in the 
MIDI domain resulted in decreased binding to miRNAs and reduced accumulation in P-
bodies presumably due to electrostatic repulsion from the negatively charged phosphate (53).  
This site is also highly conserved between different species suggesting a critical point of 
regulation.  Akt3 phosphorylates Ser387 in the L2 region increasing its association with 
GW182 and increasing translational repression (54).  Also in the L2 region of Ago2 Tyr393 
was found to be phosphorylated by EGFR under hypoxia.  This resulted in a identification of 
an miRNAs regulated by hypoxia-dependent EGFR-suppressed maturation (mHESM) 
signature of hypoxia-regulated miRNAs that have a unique loop structure that may be 
important for recognition by phosphorylated Ago2 (55).
 Ubiquitylation of Ago2 appears to be a means to regulate miRNA pathway activity.  
The mouse E3 ubiquitin ligase lin-41 co-localizes with Ago2 and Dicer in P-bodies and 
ubiquitylates them both in vitro and in vivo (56).  Gain and loss of function of lin-41 resulted 
in decrease and increased Ago2 expression, respectively and correlated with miRNA 
processing.  Ago2 is bound by the autophagy receptor NDP52 and ubiquitylated resulting in 
reduced Ago2.  Interestingly, it was only miRNA-free complexes that were targeted to 
autophagosomes suggesting under nutrient stress conditions miRNA regulation is still key 
but ubiquitylation decreases inefficiency (57).
 Upon induction of cellular stress the Argonaute family of proteins is poly(ADP-
ribosylated) by PARP-13 increasing stress granule localization and decreasing miRNA 
suppression of mRNA (58).  This is a reversible process wherein the removal of pADPr is 
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mediated by PARG.  Conversely, Ago2 is stabilized and miRNA-suppressive activity is 
increased upon hydroxylation of Pro700 by the type I collagen prolyl-4-hydroxylase (C-P4H
(I)) (59). 
1.1.8. Regulation of miRNA biogenesis by accessory proteins
 The core components of the miRNA processing pathway are necessary for global 
expression of miRNAs; however, a number of accessory proteins are able to transiently bind 
to the core components at all stages of biogenesis to both positively and negatively regulate 
miRNA biogenesis. By far the most heavily regulated step of processing known to date is the 
processing of pri-miRNA by the microprocessor complex.  Perhaps this is due to the 
increased presence of cis regulatory elements lacking in later stages of processing or it may 
simply due to a gap in knowledge regarding the complexities of later stages of processing.
 Arsenite-resistance protein 2 (ARS2) regulates miRNA processing at the very 
beginning by binding to Drosha and stabilizing pri-miRNA as they are processed co-
transcriptionally (60, 61).  
 The regulation of pri-let-7 by Lin28 is one of the best-studied accessory molecules.  
Lin28 binds to the terminal loop of pri-let-7 which inhibits proper processing by the 
microprocessor complex (62).  In an additional level of regulation Lin28 also recruits the 
terminal poly(U) polymerases TUT4 and TUT7 to uridylate the 3’ end of the let-7 precursor 
which can no longer be processed by Dicer and is targeted for degradation by DIS3L2 an 
oligo(U)-binding and processing exoribonuclease (63–67). Loss of mature let-7 is one of the 
mechanisms by which Lin28 functions as a stem cell factor.
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 Two RNA helicases, p68 and p72, are necessary for the processing of multiple pri-
miRNA through their interaction with Drosha (68, 69).  While these proteins are not capable 
of processing pri-miRNAs alone it is thought they facilitate processing by Drosha via 
structurally stabilizing the pri-miRNA.  Of the two, p68 also interacts with p53 upon DNA 
damage and TGF-β activated SMAD signal transducer (69, 70).  In a similar mechanism to 
SMADs, SNIP1 interacts with Drosha and may increase processing of pri-miR-21 (71).  
 Post-transcriptional processing of miRNAs can exhibit an extraordinary level of 
precision as is the case for hnRNP A1, which facilitates the exclusive processing of pri-
miR-18a from the polycistronic miRNA cluster miR-17~92 (72).  Accessory protein factors 
also compete for the same binding sites as with hnRNP A1 and KSRP on the terminal loop of 
pri-let-7a.  hnRNP A1 binds the loop and inhibits processing by Drosha while simultaneously 
inhibiting KSRP, a positive regulator of pri-miR-let-7a biogenesis (73), from binding the 
same region (74).  KSRP, in addition to regulating pri-miRNA, is one of the few accessory 
proteins known to regulate pre-miRNA biogenesis (75–77). 
 Estrogen receptors ERα and ERβ both have a role in miRNA biogenesis through 
interacting with p68 and Drosha (78, 79).  Following along with their known antagonistic 
roles in cancer outcomes ERα and ERβ demonstrate opposite effects in miRNA biogenesis.  
 ILF2 and ILF3 (also known as NF45 and NF90, respectively) function together to 
repress a subset of miRNA (80).  ILF3 may interact with the microprocessor through DGCR8 
in an RNA-dependent manner to transfer pre-miRNA from the microprocessor to Exportin-5 
(81).
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Fig. 1. An overview of regulators of miRNA biogenesis.
The core processing machinery is represented by Drosha/DGCR8 to process pri-
miRNAs while Dicer/Ago/TRBP process pre-miRNA.  Accessory molecules in 
green and red are activators and inhibitors of biogenesis, respectively.  RNA 
modifications are indicated by a red ‘I’.  Reprinted by permission from 
Macmillan Publishers Ltd: Nat Rev. Genet. (Krol J et al. 2010 Sep;11(9):
597-610.), copyright (2010). 
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1.1.9. Non-canonical biogenesis of miRNA
 While the core machinery processes the majority of miRNAs there are exceptions that 
bypass one or more steps.  Often this is possible due to structural features in the hairpin loop 
that allow loading directly into downstream processing complexes.  MiR-451 skips Dicer 
processing by being directly trimmed by Ago2 following Drosha processing (82–84).  Poly
(A)-specific ribonuclease (PARN) was identified as the enzyme responsible for trimming the 
3’ end of miR-451 for proper RISC loading (85).  Interestingly, trimming was not always to 
the optimal length for RISC indicating RISC can accommodate RNAs of varying lengths.  A 
limited number of miRNAs are transcribed as pre-miRNA with 5’ caps that are able to 
directly be processed by Dicer (86).  These pre-miRNAs are exported out of the nucleus 
using Exportin-1 instead of Exportin-5.  Certain miRNA classes can be cleaved from their 
primary transcripts not by the microprocessor but rather via the splicesome machinery (87, 
88).  Termed mirtrons, these miRNA merge with the canonical pathway at Exportin-5 and are 
loaded into Dicer to complete their maturation.      
1.1.10. Modification of miRNA nucleotides
 In addition to regulating miRNA biogenesis in trans as determined by protein 
complexes, cells also regulate miRNA biogenesis in cis by modifying nucleotides that affect 
biogenesis or targeting.  These alterations can range from altering nucleotides at the 5’ or 3’ 
end of the pre- or mature miRNA, or by altering the internal nucleotides, which often occurs 
at the pri- or pre-miRNA level.  Collectively, these modifications are referred to as non-
templated additions (NTAs).
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 Double-stranded RNA-specific adenosine deaminase, or ADARs, are enzymes that 
convert adenosine nucleotides to inosine nucleotides by hydrolyzing the the C6 amine (89).  
The resulting inosine is structurally similar to guanosine, which can alter base pairing and 
recognizing by other proteins.  Editing of pri-miR-142 inhibits processing from Drosha and 
facilitates cleavage by Tudor-SN, a nuclease that recognizes inosine-uracil pairs in dsRNA 
(90).  However, some miRNA demonstrate enhanced processing upon A-to-I editing 
suggesting ADARs may have a significant influence on miRNA activity (91).  Editing of 
miRNAs in their seed region can also alter the mRNAs that are targeted (92).
 While ADARs modify internal nucleotides of miRNAs multiple enzymes catalyze 
modifications to the 5’ or 3’ ends.  Uridylation of miRNAs on their 3’ end was found to 
inhibit processing by Dicer and resulted in degradation (63, 65).  TUT4 and TUT6 are part of 
a family of terminal uridyl transferases and are the key enzymes involved in uridylating 
miRNAs.  High-throughput sequencing revealed extensive uridylation of multiple miRNAs 
including mono-, di-, tri-, and poly-uridylated species (93).  Whereas uridylation destabilizes 
miRNAs, adenylation functions to stabilize them.   GLD-2 is a poly(A) polymerase that 
stabilizes adenylated miRNAs; however, poly-adenylated miRNAs may have reduced 
capacity to load into the RISC complex, which may affect their activity (94, 95).  2’-O-
methylation of miRNAs is found in plants and stabilizes miRNAs by preventing uridylation-
mediated cleavage (96, 97).  However, human miRNAs are methylated on their 5’ end.  
BCDIN3D is a RNA-methyltransferase that phospho-dimethylates 5′ monophosphate 
precursor miRNAs (98).  5’ methylation inhibits Dicer recognition and processing.  Taken 
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together, the complexity of miRNA NTA generates an exquisite diversity of ways in which 
cells can regulation miRNA levels in cis (99).  
1.1.11. Turnover of miRNAs
 The diversity of processes regulated by miRNA cover those which require a rapid 
response such as apoptosis and neurological signaling to processes requiring constant 
miRNA levels such as stem cell maintenance.  As such, miRNAs have variable half-lives 
from hours to days (100).  Relatively little is known as to what proteins are responsible for 
turnover.  In plants, degradation of mature miRNA is mediated by small RNA degrading 
nuclease 1 (SDN1), which is a 3’ to 5’ exoribonuclease (101).  Conversely, animals utilize a 
5’ to 3’ exoribonuclease, XRN-2, which requires separation of the miRNA from the RISC 
complex before it can be degraded (102).  
1.1.12. MiRNA regulatory networks
 The multi-tiered nature of miRNA processing coupled with regulation miRNA exert 
on gene expression allows cells to form distinct regulatory loops to maintain or react to a 
variety of cellular processes.  The networks are often composed of a transcription factor-
miRNA-target gene relationship.  In the broadest sense, these networks can be either 
feedforward or feedback loops that serve to propagate a signal or mitigate long-lasting 
effects, respectively (Fig 2).  For example, in the development of Drosophila sensory organs 
the transcription factor Pnt-P1 is activated by EGF to serve as a transcriptional repressor of 
Yan, ultimately leading to differentiation (103).  Pnt-P1 also stimulates the transcription of 
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miR-7, which in turn inhibits Yan forming a coherent feedforward loop (104).  This pathway 
is conserved in humans suggesting that these networks may have evolved early on and are 
necessary for proper development (105).  Incoherent feedforward loops function in noise 
buffering to maintain a signal at appropriate levels (106).  Nodal signaling, which determines 
left and right axial structures, regulated by an incoherent feedforward loop where Oct4 
activates transcription of the Nodal antagonist Lefty and its negative regulator, the miR-290-
miR-295 cluster (107).  As a result, Lefty levels are constantly kept in check.  E2F1 
transcriptionally activates and is negatively regulated by the miR-17~92 cluster of miRNA 
forming a single negative feedback loop to regulate cellular proliferation (108, 109).  Perhaps 
the best-characterized double-negative feedback loop exists between ZEB1 and ZEB2 (also 
known as Sip1) and the miR-200 family (composed of miR-200a/b/c, miR-141, and 
miR-429).  ZEB1 and ZEB2 function as transcriptional repressors of the two genomic 
clusters of the miR-200 family (see Fig 3.) and contain multiple miR-200 binding sites in 
their 3’ UTR (110, 111).  In epithelial cells, ZEB1/2 levels remain low resulting in an 
abundance of miR-200.  Upon treatment with TGF-β, ZEB1/2 are transcriptionally 
upregulated by SMAD2 resulting in loss of miR-200 transcription and an epithelial-to-
mesenchymal transition (112).
 Recently, a hypothesis regarding RNA-directed miRNA regulation has been proposed 
referred to as the competing endogenous RNA (ceRNA) hypothesis (113).  It postulates that 
the relative abundance of the mRNA targets can alter the effects of miRNAs by serving as 
molecular ‘sponges’ to dilute the effects of miRNA on other target genes.  PTEN was found 
to be regulated by ZEB2 levels in a ceRNA-dependent manner and this was largely due to 
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effects from the miR-200 family (114).  The expression of ZEB2 lead to increased Akt 
activation resulting in cellular transformation.  This represents the first instance of an mRNA 
dictating miRNA effects in a manner independent of transcription.      
 
16
Fig 2. MicroRNA regulatory networks.
A) Representation of generic FFLs.  Line with dots at the end can be transcriptional 
activators or repressors. B) Coherent FFLs two paths have the same effect on a common 
target.  C) Incoherent FFLs the target gene is both activated and inactivated through the 
actions of the transcription factor (TF). D) Feeback loops can be either single or double 
negative.  Single negative keep FBLs keep expression of either in check while double 
negative FBLs can have a runaway effect in favor of either TF or miRNA. 
1.1.13 The role of the miRNA in cancer
 Since their discovery, miRNA have been found to be critical regulators of disease and 
development.  Their role in cancer has been particularly well-established (112, 115–117).  
Much like their protein-coding counterparts, miRNAs can function as tumor suppressors or 
oncogenes depending on the genes they regulate.  
 MiR-15a and miR-16-1 are transcribed as a bicistronic primary miRNA.  The gene 
encoding them is embedded within the DLEU2 non-coding RNA, which part of the fragile 
genomic region 13q14.3 prone to translocating (118).  MiR-15a/16-1 negatively regulates the 
expression of the anti-apoptosis BCL2 gene to function as a tumor suppressor (119).  
However, when expression of miR-15a/16-1 is lost the resulting high levels of bcl-2 can lead 
to resistance to chemotherapy (120).  Moreover, induction of miR-15a/16-1 by all trans 
retinoic acid in acute promyelocytic leukemic induced differentiation via down-regulation of 
BCL2 (121).  In the development of Xenopus embryos, miR-15 and miR-16 function to 
establish a dorso-ventral gradient of Nodal ligand expression where more dorsal features 
have decreased miR-15/16 expression and consequently increased SMAD2 signaling (122).  
Cancer cells often hijack cellular programs whose origins lie in development and exploit 
them to their own advantage.  The miR-15/16 cluster is no exception to this and represents 
one of the earliest examples of cancer cells manipulating miRNA with dual roles in 
development and disease.      
 The miR-200 family represents another excellent example of miRNAs with clear 
developmental origins that go awry in cancer.  This family has garnered extensive attention, 
in part, because of its contributing role in cancer metastasis, which remains the leading cause 
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of mortality from cancer (123).  The miR-200 family was found to have two separate but 
equally important roles in metastasis.  In the first stage within the primary tumor, low 
miR-200 levels at the invasive front decrease E-cadherin expression increasing the potential 
of cells to metastasize (124–126).  However, once the cancer cell reaches the site of 
metastasis miR-200 levels are restored in a mesenchymal-to-epithelial transition (MET) (127, 
128).  These findings indicate a pleiotropic role in miR-200 function and argue that 
understanding their regulation may unlock new insights into the metastatic process.
 The miR-200 family consists of five miRNAs expressed from two different genomic 
clusters (Fig. 3).  Each cluster is under extensive transcriptional regulation, both positively 
and negatively.  Of the transcription factors listed in Fig. 3 only three are negative regulators 
of miR-200 family transcription: Slug, ZEB1, and ZEB2 (111, 129).  ZEB1 and ZEB2 work 
in concert to inhibit miR-200 expression via binding to multiple E-box domains in the two 
chromosomal loci.  The ZEB1/2-miR-200 axis also forms a distinct double-negative 
feedback loop whose balance is perturbed upon induction from external stimuli (e.g. TGF-β 
or BMPs), which often commits the cell to either an epithelial or mesenchymal lineage.        
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Fig. 3. Transcriptional regulation of the miR-200 family.
A graphical representation of the various transcription factors that bind to the miR-200b/
a/429 cluster or the miR-200c/141 cluster.  All transcription factors listed are activators 
except Slug and ZEB1/2.  TSS = transcription start site.  Not drawn to scale.
1.2 Mechanisms for studying protein-RNA interactions
 Following the sequencing of the human genome and development of evermore 
advanced sequencing technologies, a new world of RNA biology that lay hidden beyond our 
reaches due to technical limitations is suddenly exploding with richness.  The following 
sections describe the advances that have been made in developing new tools to identify and 
characterize novel protein-RNA interactions.  These sections are broken down into two broad 
categories: protein-centric and RNA-centric
1.2.1 Protein-centric techniques to study protein-RNA interactions
1.2.1.1 RNA immunoprecipitation (RIP)
 One of the earliest advances to address whether a particular protein interacts with a 
particular RNA without relying on in vitro techniques was RNA immunoprecipitation (130).  
This technique built upon existing technologies at the time for chromosome 
immunoprecipitation (ChIP) with the extra step of reverse transcription.  While ChIP and 
RIP are powerful techniques in their own right, they rely on chemical crosslinkers, which can 
result in significant background from non-specific covalent bonding during fixation.  Another 
shortcoming of RIP was the target sequence must be known to some extent. However, this 
was fixed with the development of RIP-Chip and RIP-seq that catalog bound RNAs through 
microarray hybridization or RNA deep sequencing (131, 132).
1.2.1.2 Crosslinking and Immunoprecipitation (CLIP)
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 The next major advancement in the identification of RNAs bound by a particular 
protein was through the use of UV crosslinking RNAs to the protein.  UV crosslinking had 
long been used in in vitro studies to analyze protein binding through gel shifts or filter 
binding assays.  It has the distinct advantage of generating a near zero distance covalent bond 
between protein and RNA; however, that covalent bond is irreversible preventing separating 
the RNA from the protein in downstream analyses.  Work in the lab of Robert Darnell 
conducted by Jernej Ule used this principle to his advantage to develop the CLIP 
methodology (133).  
 Later variants of the protocol incorporated high-throughput sequencing (HITS-CLIP) 
and increased crosslinking efficiency by the use of photoactivatable ribonucleosides (PAR-
CLIP) (134, 135).  Importantly, the inclusion of next-gen sequencing in these techniques not 
only allowed the identification of all the RNAs bound by a protein but also the exact location 
in which it interacts.  This can be done computationally through identifying mutations 
induced as a result of downstream applications.  In HITS-CLIP, the protein-RNA complex is 
extracted from nitrocellulose via proteinase K digestion, which leaves a couple of amino 
acids still covalently linked to the RNA.  As the reverse transcriptase is moving along the 
RNA it encounters the amino acids and skips over the nucleotide to complete the cDNA 
synthesis.  Therefore, nucleotides missing in the sequencing data indicate the exact location 
the protein was bound.  A similar bioinformatic analysis can be done with PAR-CLIP since 
the incorporation of 4-thiouridine or 6-thioguanosine in the RNA to facilitate crosslinking 
results in a thymidine to cytosine or guanosine to adenosine transition, respectively (136). 
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 The latest iteration of CLIP technologies is individual-nucleotide resolution CLIP, or 
iCLIP (137).  iCLIP takes advantage of the fact that 85% of the time the reverse transcriptase 
does not skip over crosslinked sites, rather it falls off generating a truncated product.  The 
key difference in iCLIP is circularization of cDNAs to identify the exact site of reverse 
transcriptase termination.  Different technologies can be joined together, for example, using 
photoactivatable nucleosides with iCLIP to generate PAR-iCLIP.  
 Taken together, the latest advancement in RNA sequencing technologies allow an 
unprecedented view into the RNA-binding landscape of proteins.  
1.2.2 RNA centric methods for studying protein-RNA interactions
1.2.2.1. Biotinylated RNA pulldown
 The use of biotinylated RNAs generated by in vitro transcription represents an easy 
method in which to identify proteins that bind to a particular RNA.  In this assay, cell extracts 
are mixed with synthetic biotinylated RNA probes that are captured through streptavidin 
beads or pre-bound in a column.  However, the advantage of simplicity is often outweighed 
by the significant drawbacks including binding of non-specific, highly abundant RNA 
binding proteins and the capture probes are often in large excess and not physiological levels 
giving a high false-positive and false-negative return.  
1.2.2.2. MS2-tagged RNA capture
 To overcome issues of spatial disruption during lysis and non-physiological RNA 
levels a new technique was developed using the MS2 aptamer fused to an mRNA of interest.  
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The technique is known as RNA-binding protein purification and identification (RaPID) 
(138).  The MS2 aptamer has a Kd of approximately 3 nM for the MS coat protein allowing 
very specific purification of low abundant species.
1.2.2.3. Poly(A) affinity capture of RNA-binding proteins
 Much like CLIP took advantage of the highly specific UV-induced crosslinks between 
protein and RNA to identify RNAs bound to specific protein, Castello and colleagues applied 
UV crosslinking and RNA capture to characterize genome-wide protein-RNA complexes 
(139, 140).  The assay is based upon the principle that RNA pol II substrates are 
polyadenylated and established protocols for the purification of poly-(A) RNA using oligo-
dT beads.  When cells are crosslinked in vivo before lysis poly-(A) capture the RNA one can 
evaluate the repertoire of RNA binding proteins as they exist in their cellular context.  A 
similar protocol was adapted to identify newly poly-adenylated RNAs by spiking cells with 
2-ethynyl adenosine before treating with biotin-azide and capturing with streptavidin beads 
(141).  While the later technique was used to profile RNAs by sequencing it is easy to 
extrapolate this technique could be combined with UV crosslinking to identify RBPs bound 
to newly polyadenylated RNAs. 
1.2.2.4. ChIRP and RAP antisense tiling pulldown
 The capture of poly-(A) RNA does not allow any specificity in target RNAs captured. 
The techniques of ChIRP (Chromatin Isolation by RNA Purification) and RAP (RNA 
Antisense Purification) both utilize multiple antisense biotinylated RNA probes that 
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hybridize to their target RNA and are captured by streptavidin beads (142, 143).  The use of 
multiple antisense RNAs that are ‘tiled’ against the target RNA allow the target RNA to be 
captured even if a particular antisense probe is blocked by structural features or are precluded 
by bound proteins.    
1.2.2.5. Peptide Nucleic Acids (PNAs)
 An alternative to using antisense RNAs are capture probes are peptide nucleic acids 
(PNAs).  As the name implies, PNAs contain the normal nitrogenous bases but instead of a 
sugar phosphate backbone PNAs contain an uncharged peptide backbone (144).  This unique 
chemistry allows PNAs to hybridize to complementary sequences in the absence of salts to 
neutralize the negative charge of a sugar phosphate backbone.  As such, PNAs display 
amazing strand invasive capability to hybridize to even highly structured RNAs.  While 
PNAs have not been used to capture protein-bound RNAs, they have been used to capture 
highly structured, non-polyadenylated RNAs (tRNAs) from a complex milieu of other 
cellular RNAs with very high sensitivity and specificity (145)
1.3 Rationale for the study
 Many of the proteins involved in miRNA biogenesis were originally characterize in 
the ribosomal RNA biogenesis pathway (Fig. 4).  Drosha was first characterized as RNase III 
necessary for pre-rRNA processing (146).  The RNA helicases p68 and p72 are responsible 
for 5.8S rRNA biogenesis (68).  Candida albicans Dicer is necessary for cleavage of 3’ 
unprocessed rRNA (147).  Loss of expression of Ago2 inhibits pre-rRNA processing, 
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specifically in the conversion of pre-5.8S rRNA (148). Lastly, HITS-CLIP analysis of RNA 
bound by DGCR8 indicated 21% of all RNA species bound are rRNA (27).  In this study, we 
identify and characterize two ribosome-associated proteins, nucleolin and receptor of 
ribosome binding protein 1 (RRBP1), with novel miRNA processing functions in the cell.  
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Fig. 4. An overview of ribosomal RNA biogenesis regulated by miRNA processing 
enzymes. A simplified model of rRNA processing is represented beginning with the 
conversion of the transcribed 47S rRNA precursor, which gets processed in through multiple 
stages to generate the 40S and 60S ribosomal subunits that associate to form the functional 
80S ribosome.  White boxes represent RNA sequences present in the mature rRNAs and 
black lines are cleaved and degraded flanking RNA sequences.  Dicer is responsible for 
degradation of the cleaved flanking sequences while Drosha, Ago2, p68, and p72 are 
necessary for proper formation of individual precursors.  Approximately 21% of all RNAs 
bound by DGCR8 are rRNA sequences, though no specific step in rRNA biogenesis has 
been attributed to it.    
Chapter 2: Materials and Methods
2.1. Cell Culture 
 All cell lines were purchased from ATCC (Manassas, VA) and maintained in the 
recommended media.  HEK293 were used to generate stable expressing lines while 
HEK293FT cells were used for lentiviral production.  Cell lines included non-transformed 
MCF-10A and MCF-12A; breast cancer cells MB-MDA-361, MB-MDA-453, MCF-7, T47D, 
MB-MDA-231, BT-549, Hs578T, and MB-MDA-435.  MOLM-13 and HL-60 cells were 
grow in RPMI with 10% heat-inactivated FBS. 
2.2. Antibodies and drugs
 Antibodies to nucleolin (clone 4E2, MBL International, 1:1000), FLAG M2 (Sigma-
Aldrich, 1:1000), HA (clone 16B12, Covance, 1:1000), Drosha (Cell Signaling, D28B1, 
1:500), GAPDH (Santa Cruz, SC-32233, 1:1000), and PARP (Santa Cruz, SC-1019, 1:1000), 
RRBP1 (Genetex, GTX101844, 1:1000), β-actin (Sigma Aldrich, 1:5000), ZEB1 (Novus 
Biologicals, NBP1-05987, 1:500), E-cadherin (Santa Cruz, 1:1000), p53 (Santa Cruz, 1:500) 
were obtained from the suppliers indicated.  Parthenolide was purchased from Sigma-
Aldrich. 
2.3 Plasmids and siRNA transfection
 The pCMV2-FLAG-NCL was generously donated by Paula Bates (U. Louisville) and 
previously described (148).  The TAP-tagged DGCR8 expression vector was generated by 
the Tuschl lab and was obtained through Addgene (Plasmid ID: 10921)(149). Cells stably 
transfected with the pCMV2-FLAG-NCL plasmid were selected for three weeks with 800 
µg/ml G418 and maintained with 200 µg/ml G418.  Cells transfected with pFLAG/HA-
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DGCR8 were selected in 10 µg/ml puromycin for one week and maintained with 1 µg/ml. 
The Plasmid for RRBP1 (p130 isoform) was purchased from Origene.  The p180 isoform 
was a gift from Dr. Ogawa-Goto (150) and was sub-cloned into the same pCMV6 backbone 
as the p130 isoform.  Stable lines for p130 and p180 isoforms were generated by transfecting 
MCF-10A cells with 10 µg of plasmid with GenJet Ver II, allowing them to grow for 48 
hours, and selecting with 400 µg/ml G418 for one week.  Primary miRNA for in vitro 
processing assays were reverse transcribed from cDNA using SuperScript III first strand 
cDNA synthesis kit (Invitrogen) and PCR products included approximately 200 nt of the 
flanking sequences.  The gel purified products were inserted into the pGEM-T-easy vector 
(Promega) by TA cloning and inserts verified by sequencing. Small interfering RNA were 
purchased from Dharmacon and Sigma-Aldrich and routinely achieved >70% knockdown 
efficiency.  Transfections were carried out using Pepmute (SignaGen) with 30 nM siRNA for 
72 to 96 hours before knockdown experiments were carried out.     
2.4. RNA Extraction and qRT-PCR
 RNA was extracted using Trizol according to the manufacturer’s instructions.  For 
mature miRNA analysis, RNA was reverse transcribed and quantified using the TaqMan 
miRNA Assay kit (Applied Biosystems) according to the manufacturer’s instructions.  Pri-
miRNA and mRNA expression were reverse transcribed with random hexamers using the 
High Capacity cDNA kit (Applied Biosystems).  Kapa Biosystems Sybr green or Probe 
mastermixes were used for qPCR.  
2.5. Northern blotting
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 10 µg of RNA was run on a 15% PAGE-urea gel and transferred to Brightstar-plus 
positively charged nylon membranes (Ambion, Inc.) by semidry transfer.  The membrane was 
crosslinked using a Stratalinker 1800 (Stratagene) at 0.12 J/cm2 followed by baking for 30 
minutes at 80 ºC.  Membranes were pre-hybridized in Ultrahyb-Oligo (Ambion) for 30 
minutes at 42 ºC before the addition of 106 cpm of 32P-labelled synthetic LNA probes 
(Exiqon) and incubated overnight at 42 ºC.  Membranes were washed two times for 30 
minutes at 37 ºC in 2× SSC and 0.5% SDS before being exposed on a phosphorimaging 
screen overnight.   
2.6. Cellular fractionation
 Cells were trypsinized and washed three times with PBS.  Three packed cell volumes 
(pcv) of cytoplasmic extraction (CE) buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM 
EDTA pH 8.0, 0.1 mM EGTA, 1 mM DTT) was used to resuspend the pellet.  After 15 
minutes on ice, NP-40 was added to a final concentration of 0.3%, gently mixed, and 
centrifuged at 4 ºC for 1 minute at 10,000 × g.  The supernatant was saved as the cytoplasmic 
fraction.  The pellet was washed once with two volumes of CE buffer.  The pellet was 
resuspended in 1 volume of nuclear extract buffer (20 mM Tris pH 7.9, 400 mM NaCl, 0.2 
mM EDTA pH 8.0), incubated for 30 minutes on ice, and centrifuged for 5 minutes at 10,000 
× g.  The supernatant was saved as the nuclear extract and the pellet discarded.  
2.7. Immunoprecipitation
 HEK293 cells stably expressing either FLAG/HA-DGCR8 or FLAG-NCL were 
collected, washed with PBS, and lysed in NP-40 whole cell extraction buffer (20 mM HEPES 
pH 8.0, 150 mM NaCl, 0.1% NP-40, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride 
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[PMSF], and 1 µg/mL each of leupeptin, pepstatin, and aprotonin).  2.5 µg of antibody was 
added to the 500 µl immunoprecipitation overnight at 4 ºC. RNase A (20 µg/ml) treatments 
were overnight at 4 ºC.  50 µl of Protein A/G agarose (Santa Cruz) was added to the lysates 
for 2 hours at 4 ºC. Beads were washed three times in lysis buffer (20 mM HEPES pH 8.0, 
150 mM NaCl, 0.1% NP-40) and boiled in 60 µl of 2× Laemmli sample buffer.  20 µl of the 
boiled beads and 10% of input and supernatant were resolved by SDS-PAGE, and Western 
blotted with the described antibodies.    
2.8. RNA immunoprecipitation
 RNA immunoprecipitation (RIP) was carried out as previously described with slight 
modifications (30).  HEK293 cells were trypsinized, washed twice with PBS and 
resuspended in 10 ml PBS.  Cells were crosslinked with 1% formaldehyde for 10 minutes 
followed by quenching with 0.25 M glycine for 10 minutes at room temperature and washed 
twice with PBS.  The pellet was resuspended in buffer A (5 mM PIPES [pH 8.0], 85 mM 
KCl, 0.5% NP-40) and incubated on ice for 10 minutes.  Nuclei were collected by spinning at  
2500 × g for 5 minutes at 4°C.  The pellet was washed once with buffer A without NP-40.  
The nuclear pellet was resuspended in 500 µl of buffer B (1% SDS, 10 mM EDTA, 50 mM 
Tris [pH 8.1]) and sonicated.  Insoluble material was pelleted at 14,000 × g for 10 minutes at 
4°C.  The supernatant was diluted into IP buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM 
EDTA, 16.7 mM Tris [pH 8.1], 167 mM NaCl) and incubated with 5 µg of FLAG antibody 
overnight at 4°C.  Beads were washed once with low-salt wash (0.1% SDS, 1% Triton 
X-100, 2 mM EDTA, 20 mM Tris [pH 8.1], 150 mM NaCl), high-salt wash (same as low-salt 
but with 500 mM NaCl), LiCl wash (0.25 M LiCl 1% NP-40, 1% Na Deoxycholate, 1 mM 
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EDTA, 10 mM Tris [pH 8.1]), and twice with TE buffer. Immunoprecipitated complexes 
were eluted from the beads by treatment with 100 µl elution buffer (50 mM Tris-HCl [pH 
7.5], 10 mM EDTA, 1% SDS) at 65 °C for 10 minutes.  Samples were reverse crosslinked by 
incubation for 2 hours at 42 °C and 6 hours at 65 °C in 0.5× elution buffer plus 0.5 mg/ml 
proteinase K.  RNA was extracted with Trizol and reverse transcribed in a 20 µl final volume 
using the high capacity cDNA kit (Applied Biosystems) with random primers.  Following 
reverse transcription, 5 µl of sample was analyzed by PCR with 500 nM primer concentration 
and the reaction allowed to proceed for 30-35 cycles before 10 µl of product was analyzed on 
a 2% agarose gel. 
2.9. In vitro miRNA processing assay
 The processing assay was carried out as described previously (151). Labeled primary 
miRNA were generated using the maxiscript kit (Ambion) according to the manufacturer’s 
instructions.  Briefly, 1 µg of linearized plasmid was labeled with 32P-labeled UTP.  RNA 
products were gel purified and eluted in 0.5 M NH4OAc, 1 mM EDTA, 2% SDS, overnight at 
37°C followed by ethanol precipitation.  All in vitro transcribed probes were made fresh for 
each experiment.  HEK293 cells were treated with siRNA for 48 hours before being 
collected.  Cells were washed in PBS and resuspended in IVP lysis buffer (50 mM Tris [pH 
8.0], 100 mM KCl, 0.2 mM EDTA) and sonicated.  Insoluble material was pelleted by 
spinning at 14,000 rpm for 10 minutes at 4°C.  15 µl of cell extract were mixed with 3 µl 64 
mM MgCl2, 3 µl labeled pri-miRNA (~3×104 cpm), 1 U/µl SUPERase-in (Ambion) and the 
final volume brought to 30 µl with DEPC-water.  For rescue experiments, 5 or 10 µl of beads 
from from a FLAG-nucleolin immunoprecipitation were added to the reaction.  The reaction 
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was incubated for 90 minutes at 37°C before the RNA was extracted with Trizol LS 
(Invitrogen).  Purified RNA was run on a 12.5% denaturing PAGE and exposed to a 
phosphorimager overnight.
2.10.  Dual luciferase assay
 1 × 105 cells were plated onto 6-well plates and co-transfected with 500 ng of 
miR-200b/a/429 reporters pGL3-321/+120 or pGL3-321/+120 Ebox Mut2 firefly luciferase 
plasmids (111) and 20 ng of pGL4-TK Renilla luciferase constructs (Promega) with GenJet 
ver. II (SignaGen). Dual luciferase reporter assay system (Promega) was performed 24 hr 
after transfection according to the manufacturer’s instructions, and luciferase activity was 
measured with a TD-20/20 luminometer. Each assay was performed in triplicate, and all 
firefly luciferase values were normalized to renilla luciferase readings.
2.11. Poly-(A)+ RNA purification
 Poly-A+ RNA purification from MCF-10A.vec and MCF-10A.ζ cells utilized the Poly
(A)Purist™ Kit (Ambion) according to the manufacturer’s instructions. Each purification 
was done using one 10-cm culture plate of cells.
2.12. RNA size fractionation
 RNA were fractionated into high (>200 nt) and low (<200 nt) fractions using RNAzol 
(MBL) and the small RNA isolation protocol according to the manufacturer’s instructions. 
2.13. High stringency northern blotting
Trizol purified RNA was fractionated by 10% acrylamide (19:1) denaturing 1× TBE-urea 
electrophoresis and transferred to Hybond+ nylon membranes by semi-dry transfer in 0.5× 
TBE for 1.5 hours at 20 volts.  The membranes were crosslinked with 120 mJ/cm2 UV254 and 
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baked at 80°C for 30 minutes.  Membranes were prehybridized with pre-hyb buffer  (6× SSC, 
0.1% SDS, 5× Denhardt’s solution) at 50°C for 1 hour to overnight then incubated with 12.5 
pmol of 32P-labeled locked nucleic acids (Exiqon) in Ultrahyb-Oligo hybridization solution 
(Ambion) overnight.  Washing of the membranes was as follows: 1× SSC 55°C, 1× SSC 
60°C, 1× SSC 65°C, 0.1× SSC 65°C.  Each wash was for 15 minutes.  Membranes were then 
exposed to a phosphorimager for 24-48 hours and scanned on a Typhoon Trio imager.   
2.14. Cloning of inducible miRNA lentiviral plasmids
 The pTRIPz doxycycline inducible lentiviral plasmid was linearized with XhoI and 
MluI, releasing a non-targeting shRNA.  Individual primary miRNA sequences were cloned 
from the pLenti-miR-200b/a/429 or pLenti-miR-200c/141 constructs (System Biosciences, 
Inc.) to include an additional 50 nucleotides of flanking nucleotides on either side of the 
stem-loop structures cataloged in MiRBase.  Primers are as follows 
200aF 5’ GCACTCGAGGGCTGCTCACCGCTCC 3’, 
200aR 5’ GCAACGCGTCCGCTCGGCCCTCC 3’, 
200bF 5’ GCACTCGAGCAGGAGGACGAGGCCC 3’, 
200bR 5’ GCAACGCGTAGCGGGCTGTGTGGG 3’, 
200cF 5’ GCACTCGAGCAGGGATCTGCAGCTTTTCC 3’, 
200cR 5’ GCAACGCGTAAGTGGGGAGGGGGCT 3’.  
2.15. Crosslinking and Peptide Nucleic Acid Pulldown Assay (CLaPP)
 MCF-12A vector or 14-3-3ζ overexpressing cells were plated on 500 cm2 dishes at 
~80% confluency (5 × 107 cells) in 100 mls of culture medium.  One plate was used per 
antisense peptide nucleic acid.  100 µM 4-thiouridine was added to the plates and incubated 
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for 24 hours.  Before UV crosslinking, cells were washed twice with 25 mls ice cold PBS 
with the second wash remaining on the cells.  The cells were crosslinked with 450 mJ/cm2 of 
UV365nm on ice and then gently scraped into a 50 ml conical tube and the cells pelleted.  The 
cell pellet was lysed in 2 mls CLaPP lysis buffer (50 mM HEPES [pH 7.4], 0.1% lithium 
dodecyl sulfate, 10 mM LiCl, 10 mM Ribonucleoside Vanadyl Complex (NEB)).  Lysates 
were incubated for 10 minutes on ice then centrifuged at 20,000 × g for 15 min at 4°C.  The 
pellets were discarded and the supernatant treated with 2 µl TurboDNase at 37°C for 10 
minutes.
 Peptide nucleic acids that were antisense to the basal stem of specific precursor 
miRNA (see Table 1 for sequences) were added to a final concentration of 1 nmol in 2 mls 
and incubated for 30 minutes at 55°C to allow hybridization of PNAs to their target RNAs.  
After hybridization the samples were brought down to room temperature and 50 µl pre-
equilibrated Nanolink 0.8 µm streptavidin magnetic beads were added to the lysates and 
incubated for 30 minutes at 37°C.  The beads were washed once in CLaPP low salt wash (50 
mM HEPES [pH 7.4], 0.5% LDS), once in CLaPP high salt wash (50 mM HEPES [pH 7.4], 
0.5% LDS, 500 mM LiCL), once in low salt wash, once in CLaPP lysis buffer, and once in 
RNase digestion buffer (50 mM Tris [pH 7.4], 50 mM NaCl, 0.01% Triton X-100, 5 mM 
MgCl2).  Beads were resuspended in 20 µl RNase digestion buffer containing 1 unit RNase 
A, 40 units RNase T1, 0.002 units RNase V1 and digestion allowed to proceed for 10 
minutes at 37°C before stopped by the addition of NuPAGE loading buffer.  Samples were 
heated at 70°C before being loaded onto a 4-12% NuPAGE gradient gel and run in MOPS 
running buffer.  Samples were stained with coomassie blue to avoid detection of partially 
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undigested RNAs by silver staining.  Individual protein bands were excised from the gel and 
send for mass spectrometry identification.   
2.16. Identification of RRBP1-bound RNAs by iCLIP
 HEK293 cells were transfected with 5 µg of pCMV6-p130 or pCMV6-p180 and 24 
hours later each plate was split 1:2 and incubated with 100 µM 4-thiouridine (Sigma) for an 
additional 24 hours.  The cells were washed with PBS twice and UV-crosslinked cells 
irradiated with 450 mJ/cm2 of UV365 while on ice.  Cells were scraped and centrifuged at 150 
× g for two minutes at 4°C and the PBS removed.  Cell pellets were snap frozen in liquid 
nitrogen and stored at -80°C for later use.   
 After thawing, cell pellets were lysed in iCLIP lysis buffer (50 mM HEPES [pH 7.4], 
100 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 
protease inhibitor cocktail), followed by sonicating three times at 3 watts in 10 s bursts while 
on wet ice.  After sonication the lysates were mixed with a 1:250 dilution of RNase I (100 
units/µl) in PBS along with 2 µl TurboDNase and incubated at 37°C for 5 minutes.  The 
lysates were centrifuged at 20,000 × g for 15 minutes at 4°C.  A 15 µl aliquot was saved as 
input protein levels and the remainder of the supernatant was incubated with 10 µg 
biotinylated FLAG antibody pre-bound to Nanolink 0.8 µm magnetic streptavidin beads for 
two hours at 4°C.  The beads were collected on a DynaMag magnetic rack and 15 µl of 
supernatant collected to determine immunoprecipitation efficiency.  The beads were washed 
twice in high salt wash buffer (50 mM HEPES [pH 7.4], 1 M NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% sodium deoxycholate), and washed three times in PNK buffer (20 mM 
HEPES [pH 7.4], 0.2% Tween-20, 10 mM MgCl2).  
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 The 3’ end of the RNA was dephosphoryalted by incubating the beads with 0.5 µl T4 
PNK, 0.5 µl RNasin, 15 µl DEPC-H2O, 5 µl 5 × PNK dephosphorylation buffer (350 mM 
Tris [pH 6.5], 50 mM MgCl2, 5 mM DTT) for 20 minutes at 37°C.  The beads were washed 
once with PNK wash buffer, twice with high salt wash buffer, and twice with PNK wash 
buffer.  
 The L3 adapter sequence (5’[phos] AGATCGGAAGAGCGGTTCAG/ddC/) that 
were 5’ phosphorylated and protected on the 3’ end with dideoxycytosine were adenylated 
using the DNA adenylation kit (NEB) following the manufacturer’s instructions and made to 
a final concentration of 20 pmol/µl.  The adapters were ligated to the 3’ end of the 
dephosphorylated RNA by T4 RNA ligase in iCLIP ligation buffer (50 mM HEPES [pH 7.4] 
10 mM MgCl2, 1 mM DTT, 10% PEG 400).  The reaction was incubated in a thermomixer at 
1100 RPM at 16°C for 16 hours.  The beads were washed once with PNK wash buffer, twice 
with high salt wash buffer, and twice in PNK wash buffer.
 Ligated protein:RNA complexes were 5’ phosphorylated with γ32P ATP with PNK for 
detection and isolated of crosslinked RNA.  The reaction was washed once in PNK wash 
buffer and RRBP1 was eluted from the beads by incubating at 70°C in NuPAGE loading 
buffer for 5 minutes.  Samples were run on a 4-12% NuPAGE bis-tris gel in MOPS NuPAGE 
running buffer then transferred to a 0.45 µm nitrocellulose membrane in 2 × MOPS transfer 
buffer by semi-dry transfer.  The membrane was washed in PBS and exposed to x-ray film at 
-80°C for one hour to detect crosslinked complexes.  The film was used as a mask to cut 
fragments from nitrocellulose that were incubated with proteinase K in PK buffer (100 mM 
HEPES [pH 7.4], 50 mM NaCl, 10 mM EDTA) for 20 minutes at 37°C and then incubated 
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with PK buffer plus 7 M urea for an additional 20 minutes.  Released RNA was isolated by 
addition of 400 µl phenol/chloroform [pH 6.7] and separation in a Phase Lock Gel Heavy 
tube according to the manufacturers instructions.  The aqueous layer was precipitated by 
adding 40 µl 3 M sodium acetate [pH 5.5] and 1 ml 100% ethanol with 0.75 µl glycoblue and 
stored at -20°C overnight.  RNA was precipitated by spinning at 20,000 × g for 20 minutes at 
4°C and washed with 80% ethanol.
 RNA pellets were resuspended in 5 µl H2O and mixed with 1 µl barcoded reverse 
transcription primer and 1 µl 10 mM dNTP mix then heated to 70°C for 5 minutes and 
returned to 25°C.  Superscript III reverse first strand mix was added according to the 
manufactuer’s instruction and incubated at 25°C for 5 min, 42°C for 20 minutes, 50°C for 40 
minutes, 80°C for 5 minutes, and the temperature held at 4°C.  RNA was degraded from the 
cDNA mix by adding 1.65 µl 1M NaOH and incubating at 98°C for 20 minutes and 
neutralized by adding 20 µl 1 M HEPES [pH 7.4].  cDNA was precipitated by adding 350 µl 
TE, 40 µl NaOAc, 0.75 µl glycoblue, and 100% ethanol at -20°C overnight.
 cDNA was isolated into high, medium, and low molecular weights by running 
precipitates on a pre-cast 6% TBE-urea gel.  Gel slices were isolated using bromophenol blue 
and xylene cyanol dyes as markers corresponding to nucleotides ranging from 70-150 
nucleotides.  The cDNA was eluted from the gel fragments by first fragmenting slices 
through a 0.65 ml tube with a hole punched in the bottom by a 21-gauge syringe and spinning 
at 16,000 × g for 2 minutes into a 1.5 ml tube then incubating the fragments in 10 mM Tris 
[pH 8.0], 0.3 M NaCl, 10 mM EDTA for two days at 4°C.  The eluted cDNA was separated 
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from gel fragments by spinning in a Costar cellulose acetate spin filter with a 1 cm Whatman 
glass pre-filtered inserted in the top and spinning at 16,000 × g for 2 minutes.  Eluted cDNA 
was precipitated overnight at -20°C by adding 0.75 µl glycoblue and 1 ml 100% ethanol.  
 The cDNA was circularized using the CircLigase II kit (Epicentre Bio) by incubating 
at 60°C for one hour.  The BamHI cut oligonucleotide 
(GTTCAGGATCCACGACGCTCTTC/ddc/) was then annealed by adding 10 pmol of the 
oligonucleotide with 3 µl Fast digest buffer (Thermo) and the volume brought to 30 µl.  
Annealing was achieved by incubating at 95°C for 2 minutes and successively decreasing the 
temperature 1°C every 20 seconds until the temperature reached 25°C.  Circular cDNA was 
linearized by adding 2 µl BamHI (NEB) to each reaction and incubated for 30 minutes at 
37°C followed by 5 minutes at 80°C.  The digested cDNA was precipitated as previously 
described.  
 Library amplification using the Solexa P5 and P3 sequencing primers was 
accomplished using the Accurprime Supermix I following the program (94°C 2 min, 27-35 
cycles of: 94°C 15 s, 65°C 30 s, 68°C, 30 s, and a final extension of 3 minutes at 68°C. 
Optimal cycles were determined by gel analysis and the remainder of the library prepared 
using the optimized cycles.  The individual barcoded samples were pooled and gel purified as 
described above, ethanol precipitated, and resuspended in 30 µl of 10 mM Tris for Illumina 
single read 50-nucleotide sequencing.  
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Chapter 2: Nucleolin interacts with the microprocessor to affect biogenesis of miR-15a/
miR-16-1.
3.1. Introduction
 MicroRNA (miRNA) are short ~21 nucleotide single-stranded noncoding RNA that affect 
gene expression by inhibiting translation or degrading mRNA targets by binding to their 3’ 
untranslated region (3’UTR) (1). Transcripts from miRNA-encoding genes generate primary 
miRNA (pri-miRNA) that vary in size from one to tens of kilobases and contain a 5’ cap and 
a poly (A) tail.  These pri-miRNA are processed in the microprocessor complex composed of 
Drosha and DGCR8 into 60-90 nucleotide precursor miRNA (pre-miRNA) (8).  After being 
exported to the cytoplasm by Exportin5 and Ran-GTP, pre-miRNAs are cleaved by Dicer, 
which transfers the double stranded RNA to the Argonaut complex to generate the mature 
miRNA (12–14).  
 The miRNA biogenesis pathway is tightly regulated with numerous other proteins 
transiently associating with the individual complexes to either stimulate or inhibit processing. 
For example, transient interaction of p53, p68 and p72 with Drosha increases the processing 
of a subset of miRNA (69, 70). Negative regulators of miRNA processing include the 
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estrogen receptor, NF45/NF90 complexes, and Lin28 (62, 78, 80).  The AU-rich binding 
protein KSRP can interact with both the microprocessor and Dicer complexes and affect their 
function (75, 76).  The effect of these regulators on miRNA processing can be very specific, 
as is the case of hnRNP A1, which facilitates the specific processing of miR-18a from the 
polycistronic miRNA miR-17~92 and Lin28, which blocks the biogenesis of let-7 family 
miRNA (62, 152).  While KSRP and Lin28 are the only two regulatory proteins known to 
affect Dicer, most of the transient effectors characterized thus far interact exclusively with 
the microprocessor complex, suggesting that this may be a critical step in the regulation of 
miRNA expression.      
 An interesting parallel exists between miRNA biogenesis and ribosomal RNA (rRNA) 
biogenesis with a number of proteins having important roles in both pathways.  Drosha was 
originally identified for its role in rRNA biogenesis, cleaving the 48S pre-rRNA into the 12S 
rRNA intermediate (146).  Both p68 and p72 are responsible for cleavage of the 12S rRNA to 
generate the mature 5.8S rRNA species (68, 153).  Additionally, Dicer has recently been 
found to associate with the chromatin encoding rRNA (154).  Depletion of either Dicer or 
Ago2 results in an accumulation of 5.8S rRNA species indicating they are necessary for 
processing (155).  Recently, it was found that Drosha co-localizes with nucleolin in the 
nucleolus to increase the biogenesis of a mouse long non-coding RNA mrhl, which is a 2.8 
kilobase RNA that gets cleaved into an 80 nucleotide RNA that can be further processed into 
a 21 nucleotide RNA by Dicer (156).  Strikingly, this pathway, like that of rRNA biogenesis, 
is very similar to the miRNA biogenesis pathway with regards to proteins and RNA 
substrates.
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 Nucleolin has long been known as a protein critical for rRNA biogenesis (157).  Evidence 
suggests that it may also have a role as an accessory protein in miRNA biogenesis.  Nucleolin 
is predominantly a nucleolar-localized protein; however, in a number of different cancers 
nucleolin is found largely in the cytoplasm (158–161).  In the cytoplasm, nucleolin functions 
to stabilize the mRNA of bcl-2, thereby inhibiting apoptosis (158).  When cytoplasmic levels 
of nucleolin are decreased upon treatment with all-trans retinoic acid (ATRA) the levels of 
miR-15a and miR-16 increase in both acute promyelocytic leukemia (APL) cell lines and 
patients with APL treated with ATRA (121, 161).  MiR-15a and -16 have been shown to 
target bcl-2 mRNA and are greatly decreased in chronic lymphocytic leukemia, where 
nucleolin is predominantly localized to the cytoplasm (119, 158).
 Therefore, we sought out to investigate the role of nucleolin in controlling the 
expression of miR-15a and miR-16.  We determined how overall expression of nucleolin and 
its cellular localization impacts miRNA expression.  Additionally, we characterized 
nucleolin’s interaction with components of the biogenesis pathway and with miRNA directly.
3.2. Results
3.2.1. The expression of miR-15a and miR-16 correlates with nucleolin expression
 To determine whether nucleolin expression impacts the levels of miRNA, nucleolin 
was knocked down with siRNA and cancer associated mature miRNA assessed by qRT-PCR.  
As a positive control, Drosha was also knocked down (Fig. 5A).  As expected, all mature 
miRNA were decreased in Drosha knockdown to 25-50% of control siRNA cells (Fig. 5C).   
In nucleolin knockdown cells, five miRNA were significantly reduced.  Because none of the 
miRNA tested were increased upon loss of nucleolin we investigated whether nucleolin 
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directly controlled their expression through processing.  Primary miRNA levels were 
analyzed since loss of proteins involved in processing typically cause an increase in primary 
miRNA while mature miRNA decrease (8, 68).  All primary miRNA increased in Drosha 
knockdown while only two primary miRNA, miR-15a and miR-16, increased in the absence 
of nucleolin.  This suggests nucleolin may directly control the expression of these two 
miRNA while the other miRNA decreased in the absence of nucleolin may be through 
indirect mechanisms.  To determine if the opposite held true when nucleolin is increased, 
MCF-7 cells were stably transfected with a CMV-driven expression vector containing FLAG-
tagged nucleolin and determined miRNA expression by real-time PCR.  We were able to 
achieve about a two-fold increase in nucleolin expression (Fig 5B).  Upon overexpression of 
nucleolin, the levels of mature miR-15a and miR-16 increased approximately 2.5 fold (Fig. 
4D). Two other miRNA, miR-100 and miR-31 increased significantly with miR-31 
increasing nearly 80-fold.  This increase may be transcriptionally regulated because the pri-
miRNA for miR-31 significantly increased in nucleolin overexpressing cells.  Pri-miRNA for 
miR-15 and miR-16 also increase, however; this may be indirectly regulated through c-myc.  
Nucleolin can inhibit c-myc through formation of a G-quadruplex in c-myc’s promoter and c-
myc can transcriptionally inhibit miR-15a and miR-16 (162, 163). An interesting observation 
was that nucleolin expression inversely correlates to Drosha expression (Fig. 5A and 5C).  It 
is possible this relationship is the cells way of compensating for altered ribosome biogenesis, 
as this is a common function between the two.  We speculate that upon loss of nucleolin the 
cell tries to compensate by increasing Drosha and while nucleolin is plentiful there is less of 
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Figure 5. Nucleolin expression correlates with miR-15a and miR-16 expression.
A) Expression of Drosha and nucleolin 72 hours following siRNA treatment  B) 
Expression of stably expressed FLAG-tagged nucleolin in MCF-7 cells.  C) Real time 
PCR analysis of mature miRNA (top) and primary miRNA (bottom) in cells with Drosha 
or nucleolin knocked down.  Results are normalized to U6 snoRNA expression. D) Real 
time PCR analysis of mature miRNA (top) and primary miRNA (bottom) in cells 
overexpressing nucleolin.  Error bars = SEM
a need for Drosha in ribosome biogensis.  All together, these data are consistent with the 
hypothesis that nucleolin plays an ancillary role in the biogenesis of miR-15a and miR-16.
3.2.2. Induced cytoplasmic nucleolin inhibits processing of primary miRNA  
 Clinical data from CLL patients shows that nucleolin is localized primarily in the 
cytoplasm, which leads to increased bcl-2 mRNA levels (158).  Because miR-15a and 
miR-16 are known to target bcl-2 mRNA, we sought to determine whether cytoplasmic 
nucleolin could lead to decreased levels of miR-15a and miR-16.  We found that when 
MOLM-13 acute myelogenous leukemia cells are treated with parthenolide, a natural product 
small molecule that affects multiple signal transduction pathways, it induces a dramatic 
increase in cytoplasmic nucleolin levels (Fig. 6A).  Analysis of mature miRNA by qRT-PCR 
revealed a significant decrease in both miR-15a and miR-16 concurrent with cytoplasmic 
localization of nucleolin (Fig. 6B).  To determine whether treatment with parthenolide 
decreased the transcription of these miRNA the pri-miRNA were amplified by PCR.  
Astonishingly, we found not a decrease but rather an increase in the pri-miRNA precursor of 
miR-15a and miR-16 (Fig. 6C).  Given this finding, we analyzed the precursor species by 
Northern blot and found that levels of the pre-miR-15 and -16 precursors decreased similarly 
that of the mature miRNA following parthenolide treatment (Fig. 6D). These data are similar 
to that observed when either Drosha or DGCR8 are knocked down, resulting in a decrease of 
mature species and an increase in the primary precursors (8).  While it was clear that 
nucleolin increased in cytoplasmic localization, it appeared nucleolin did not decrease in 
nuclear expression despite the miRNA expression indicating this.  Nucleolin normally resides 
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Figure 6. Decreased association of nucleolin with the microprocessor complex affects 
miRNA processing. 
A) MOLM-13 cells were treated with 10 µM parthenolide (PN) for the times indicated.  
The efficiency of cellular fractionation was determined using GAPDH and PARP.  
Cleaved PARP is visible in the cytoplasm after 8 hours of treatment.  B) Expression of 
mature miRNA following treatment with PN for the times indicated as determined by 
qRT-PCR and normalized to U6 snoRNA expression.  Error bars = SEM.  C) PCR of 
primary miRNA following treatment with PN with actin as a loading control.  D) 
Northern blot analysis of RNA from MOLM13 cells treated with PN.  Quantitation of 
precursor species is indicated below each lane and is normalized to U6.  E) Western blot 
of nucleolin immunoprecipitation from nuclear extracts to interrogate the interaction of 
nucleolin with Drosha in the nucleus following PN treatment.
in the nucleolus and is not evenly dispersed throughout the nucleus.  Upon activation of p53, 
nucleolin leaves the nucleolus (164).  We previously reported that parthenolide potently 
activates p53 (165).  It has been reported that Drosha co-localizes with nucleolin in the 
nucleolus and so we hypothesized that the interaction between nucleolin and Drosha is 
decreased upon re-localization of nucleolin out of the nucleolus.  To determine this 
MOLM13 cells were treated with parthenolide and nucleolin immunoprecipitated from 
nuclear extracts.  We found that nucleolin interacts with Drosha and this interaction is 
disrupted upon treatment with parthenolide (Fig. 6E).  From these data we concluded that 
nucleolin facilitates the processing of miR-15a and miR-16 likely through the microprocessor 
complex, which is localized exclusively in the nucleus.  Upon cellular stress nucleolin alters 
its localization and is spatially separated from the microprocessor complex, which is 
responsible for the cleavage of primary miRNA to generate the precursor.   We suspect that in 
the absence of nucleolin the microprocessor can less effectively cleave the primary species 
resulting in the observed buildup of the pri-miRNA for miR-15a and miR-16.  Conversely, 
when the acute promyelocytic leukemia (APL) HL-60 cell line was treated with all-trans 
retinoic acid (ATRA), nucleolin was observed to move from the cytoplasm to the nucleus 
(Fig. 7A).  The increased nuclear localization of nucleolin was accompanied by significant 
increases in mature miR-15a/16 (Fig. 7B).  The primary miRNA were not increased in these 
cells following treatment (Fig. 7C) indicating post-transcriptional regulation.
46
47
Figure 7. Treatment with all--trans retinoic acid (ATRA) induces nuclear localization 
of nucleolin and increased miRNA expression.
A) HL-60 acute promyelocytic leukemia cells were treated with 1 µM ATRA to decrease 
cytoplasmic localization of nucleolin and increase nuclear localization as described 
previously (25).  B) Expression of mature miR-15a/16 in cells treated with ATRA closely 
correlates nucleolin localization.  All points are normalized to DMSO-treated cells 
(dashed line). C) Primary miRNA expression shows no significant change in expression 
over time as determined by qRT-PCR normalized to DMSO-treated cells (dashed line).   
3.2.3. Knockdown of nucleolin ablates processing of primary miRNA
 To further validate that nucleolin is involved in the processing of primary miRNA, 
nuclear-localized nucleolin was induced in MCF-7 cells.  This was achieved through 
treatment of MCF-7 cells with parthenolide. Interestingly, in MCF-7 cells parthenolide 
induced nuclear-localized nucleolin, whereas in MOLM-13 AML cells parthenolide increased 
cytoplasmic levels of nucleolin (Fig 6A and 8C).  This differential effect was independent of 
parthenolide’s capacity as a specific HDAC 1 inhibitor, which is the same in both cell lines 
(165).  Upon analyzing the miRNA expression in parthenolide-treated and DMSO-treated 
control cells, there was a substantial (>12-fold) increase in mature miR-15a in parthenolide-
treated cells.  MiR-16 expression also significantly increased in parthenolide-treated cells, 
albeit to a lesser extent (~2.5 fold).  This could be due to the fact that the steady-state levels 
of mature miR-16 are over 50-fold higher under normal conditions than miR-15a and may 
not be as easily increased as miR-15a.  To rule out that all miRNA are altered upon PN 
treatment we also analyzed let-7a expression, which was not altered following changes in 
nucleolin expression (Fig. 4B and 4D).  Let-7a mature miRNA remain unchanged.  To 
determine whether the large increases observed were truly due to nucleolin and not the 
effects of parthenolide, nucleolin or RISC-free control siRNA were transfected into MCF-7 
cells and 72 hours later treated with parthenolide.  Incredibly, when nucleolin is dramatically 
knocked down (Fig. 8A inset) the increase in miR-15a is almost completely ablated, as the 
resulting miRNA levels were close to that of the DMSO-treated cells while the RISC-free 
control remained comparable to untransfected cells.  Similarly, miR-16 in nucleolin 
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knockdown cells decreased significantly from the RISC-free control group following 
parthenolide treatment (Fig 8A).  
 We next sought to determine how the primary miRNA precursors of miR-15a and 
miR-16 were affected by the induced nuclear localization of nucleolin.  From the data shown 
in figure 2 we concluded that cytoplasmic nucleolin inhibited the processing of pri-miRNA 
species as determined by their increase.  Upon analyzing the pri-miRNA following 
parthenolide treatment in either the untransfected or RISC-free control groups we observed 
an absence of pri-miR-15a and pri-miR-16.  These data indicate that in the presence of 
increased nuclear nucleolin the primary miRNA are efficiently processed into precursor and 
ultimately mature miRNA resulting in exhaustion of the pool of primary species in the cell.  
However, after knocking down nucleolin a significant portion of the primary species persists, 
comparable to the levels observed in the DMSO-treated controls (Fig. 8B).  The levels of pri-
let-7a, like mature let-7a, were unaltered in all conditions.  From these data we conclude that 
it is likely not off-target effects from parthenolide that induces the biogenesis of pri-miR-15a/
16 but rather the increased nuclear localization of nucleolin.  In the absence of nucleolin, the 
microprocessor complex appears unable to efficiently upregulate the processing of the pri-
miRNA, resulting in no increase of mature miR-15a and miR-16 species.
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Figure 8. Primary miRNA processing is inhibited in the absence of nucleolin. 
A) MCF-7 cells were treated with 25 µM parthenolide (PN) or DMSO for 3 hours before 
RNA extraction and qRT-PCR of mature miRNA.  Nucleolin knockdown and RISC-free 
siRNA control cells were transfected 72 hours prior to parthenolide treatment.  B) PCR 
amplification of primary miRNA from RNA extracted in (A).  C) Cellular fractionation of 
MCF-7 cells following treatment with PN demonstrating the increased nuclear nucleolin 
levels at the 3 hour time point used in (A and B).  
Nucleolin interacts with the components of the microprocessor independent of RNA
 The data generated from the altered localization of nucleolin demonstrate that 
nucleolin is only able to exert an effect on miR-15a/16 expression while in the nucleus and 
that it is the primary miRNA that are affected, indicating nucleolin may interact with the 
microprocessor complex.  To determine if it affects processing by directly binding to the 
proteins in the microprocessor complex composed of Drosha and DGCR8 an 
immunoprecipitation experiment was conducted. HEK293 cells stably expressing tandem 
affinity purification (TAP) FLAG and HA tags at the N-terminus of DGCR8 were used.  
Lysates were immunoprecipitated with either FLAG or HA antibody to bring down DGCR8 
and western blot was used to determine if nucleolin was present in the pulldown.  HEK293 
cells not transfected with the expression plasmid were used as a control for non-specific 
binding of FLAG or HA.  Nucleolin was not present in the IgG isotype control pulldown or 
in the lysates not expressing DGCR8 with FLAG or HA but strongly came down with both 
FLAG and HA in FLAG/HA-DGCR8 expressing cells (Fig 9A).  Nucleolin is a well-known 
RNA binding protein and to rule out the possibility that nucleolin came down as a result of 
tethering to a common RNA the lysates were exhaustively treated with RNase A.  The 
interaction between DGCR8 and nucleolin persisted even after complete digestion with 
RNase A indicating a protein-protein interaction.  
 Nucleolin has been shown to co-localize with Drosha to affect the processing of a 
long non-coding RNA mrhl in the nucleolus (156).  However, in that study a direct 
interaction was never investigated. FLAG-tagged nucleolin was immunoprecipitated in 
HEK293 lysates and probed for Drosha binding.  No interaction was found when FLAG-
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nucleolin alone was used in the immunoprecipitation (Fig. 8B).  When lysates were treated 
with RNase A, a weak band appeared, which could be the result of freeing Drosha from other 
complexes dependant on RNA.  We consistently found that Drosha was decreased in the 
supernatant and yet failed to appear in the immunoprecipitation.  We surmised that it was in 
fact binding to nucleolin but was lost during the washes due to a weak interaction or unstable 
complex.  To overcome this issue 5% polyethylene glycol with molecular weight 8000 Da 
was used in the wash buffer to reduce the void space during the washes.  The addition of 
PEG to the wash buffer reduced the loss of Drosha and revealed that Drosha also interacts 
with nucleolin.  
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Figure 9. Nucleolin interacts with the microprocessor complex.
A) Immunoprecipitation of DGCR8 from whole cell extracts of HEK293 expressing FLAG/
HA-DGCR8.  IgG isotype control in DGCR8-expressing cells and FLAG or HA in cells not 
expressing tagged DGCR8 served as controls for non-specific interactions. RNase A 
treatment indicates incubation with 20 µg/ml overnight.  Supernatant represents 10% of 
total supernatant.  B) Immunoprecipitation of FLAG-nucleolin from HEK293 cells whole 
cell extracts and immunoblotting for Drosha.  PEG 8000 indicates that polyethylene glycol 
m.w. 8000 was added to the wash buffer to a final concentration of 5% (w/v). 
3.2.5. Nucleolin binds to primary miR-15a and miR-16
Nucleolin is a well-known RNA binding protein.  It has no known catalytic function in RNA 
cleavage but it necessary for rRNA cleavage (157).  The proposed mechanism is that 
nucleolin holds the RNA in proper conformation to be cleaved by other components of 
rRNA biogenesis.  Furthermore, nucleolin has been shown to co-localize with Drosha to 
affect the biogenesis of a long non-coding RNA but cannot itself cleave the RNA (156).  We 
determined that nucleolin binds to the components of the microprocessor but sought to 
determine if it also binds to the primary miRNA, perhaps to stabilize its conformation for 
cleavage. An RNA immunoprecipitation experiment was conducted with HEK293 cells 
overexpressing either nucleolin or DGCR8, as a positive control.  After crosslinking and 
sonication, nucleolin or DGCR8 were immunoprecipitated with FLAG antibody or IgG 
control and the presence of primary miR-15a, miR-16, or let-7a was determined by PCR.  
DGCR8 bound to pri-miR-15a and -16, as expected (Fig 10).  When primary miR-15a and 
miR-16 were amplified from nucleolin immunoprecipitates we found that nucleolin bound 
them to a level equal to that of DGCR8 indicating that nearly the entire pool of pri-miR-15a 
and -16 in the cell that is bound by DGCR8 also contains nucleolin.  To determine if binding 
of nucleolin is specific, we also amplified pri-let-7a from both pools of extracted RNA and 
found it was only bound by DGCR8 but not by nucleolin (Fig. 10).  The background 
contamination from genomic DNA was minimal as PCR amplification of extracted RNA 
without reverse transcription (No RT) revealed no amplification of primary miRNA (Fig. 9). 
It also appears that a large pool of primary miR-15a and miR-16 exists in the cell that is 
poised to be processed but is not actively engaged with DGCR8 or nucleolin since the bound 
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RNA was less than 1% of the total pool.  This seems plausible since both miRNA are 
implicated in controlling the apoptotic response of a cell in addition to controlling the cell 
cycle, both of which require a rapid response to stimuli best provided from an inactive pool 
of unprocessed miRNA. 
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Fig. 10. Nucleolin binds to pri-miR-15/16.
HEK293 cells expressing either FLAG-nucleolin or FLAG/HA-DGCR8 were 
immunoprecipitated with either IgG or FLAG and the bound primary miRNA 
amplified by PCR.  No RT indicates purified RNA from immunoprecipitates that was 
not reverse transcribed before PCR analysis.  Input represents 0.1% of total RNA. 
3.2.6. Nucleolin affects the processing of primary miRNA in vitro
 To confirm that nucleolin can indeed facilitate the processing of primary miRNA we 
conducted an in vitro microRNA processing assay.  Whole cell extracts were generated from 
HEK293 cells with nucleolin knocked down or Drosha knocked down as a positive control 
for defective processing (Fig 11A).  In extracts with nucleolin knocked down, nucleolin was 
reconstituted by the addition of immunoprecipitated FLAG-tagged nucleolin (Fig 11B).  Both 
control extracts (no transfection and control siRNA) were able to process the radiolabeled 
pri-miRNA to generate the precursor species for miR-15a/16 and let-7a (Fig. 11C).  When 
Drosha was knocked down, the extracts were unable to generate the predicted precursors for 
both miRNA.  Extracts lacking nucleolin were unable to process miR-15a/16 but could still 
generate the precursor for let-7a.  The addition of immunoprecipitated nucleolin could rescue 
the processing in nucleolin deficient cells indicating it can directly affect miRNA processing.  
There was no affect on let-7a processing with nucleolin rescue.  Taken together, these data 
indicate nucleolin directly and specifically affects the processing of primary miR-15a and 
miR-16.
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Figure 11. Nucleolin directly affects processing of primary miR-15a and miR-16.
A) HEK293 cells treated with either Drosha or nucleolin siRNA.  B) Reconstituted nucleolin 
in nucleolin knockdown extracts.  FLAG-nucleolin was immunoprecipitated from HEK293 
stable cells and mixed at either 1 or 2 concentrations.  2 reconstitution restores nucleolin to 
levels equivalent in untransfected extracts.  C) In vitro processing of primary miRNA.  Gel 
purified in vitro transcribed RNA was incubated with 15 µl of cell extracts from (A) for 90 
minutes at 37C and analyzed on a 12.5% denaturing gel.  Precursors of the predicted size are 
indicated. 
3.3. Discussion
 In this study, we demonstrate that nucleolin affects the expression of miR-15a/16.  We 
also found that cellular localization of nucleolin is important for its function and concluded 
that this is most likely because of its interaction with the microprocessor complex in the 
nucleus.  When nucleolin is knocked down or is altered in its localization the processing of 
primary miRNA is significantly decreased indicating it is necessary for proper expression of 
miR-15a/16.  In addition, we found that nucleolin can bind directly to the primary miRNA 
species for miR-15a/16 and facilitate their processing in vitro.  Taken together, these data 
suggest that nucleolin acts as an accessory protein to the microprocessor complex to facilitate 
miRNA biogenesis.  As is the case with other accessory proteins involved in miRNA 
biogenesis nucleolin does not globally regulate miRNA processing like Drosha or DGCR8. 
 We initially identified a correlation between nucleolin localization and miR-15a/16 
expression before exploring how nucleolin may affect their expression.  Nucleolin has been 
characterized as an AU-rich binding protein that stabilizes the 3’UTR of bcl-2 mRNA upon 
cytoplasmic localization (158).  The result of this is increased bcl-2 protein expression and 
inhibition of apoptosis – one of the hallmarks of cancer.  MiR-15a/16 have been well-
characterized as negative regulators of bcl-2 mRNA and decreased expression of these 
miRNA is noted in numerous cancers.  In some instances decreased miR-15a/16 expression is 
due to chromosomal deletions; however, this only accounts for about half the patients with 
increased bcl-2 indicating other mechanisms must be present (119).  Our data indicates that 
increased cytoplasmic localization of nucleolin in cancer may be partially responsible for 
reduced miR-15a/16 expression.  We propose that nucleolin plays a critical role in the 
59
balance between miR-15a/16 and bcl-2 mRNA to control the induction of apoptosis.  Under 
normal conditions, nucleolin is localized in the nucleus of cells, specifically in the nucleolus, 
where it associates with the microprocessor complex. This results in an increase in 
expression of mature miR-15a/16, which then downregulates bcl-2 mRNA (Fig. 11).  After 
induction of cellular stress, nucleolin leaves the nucleus to stabilize the 3’UTR of bcl-2 while 
simultaneously decreasing the expression of miR-15a/16 thereby further stabilizing bcl-2 
mRNA.
 A number of proteins involved in miRNA processing are also essential for ribosomal 
RNA biogenesis including Drosha, one of the core proteins in the microprocessor complex 
(146).  It is tempting to speculate that miRNA processing evolved from the existing 
machinery required for rRNA.  Indeed a number of miRNA have been shown to localize to 
the nucleolus, a region long-believed to be exclusive to rRNA biogenesis (166, 167).  
Moreover, nucleolin co-localizes with Drosha in the nucleolus to facilitate the processing of 
mrhl, a long non-coding RNA in mice.  The transcript of this lncRNA is 2.8 kilobases, which 
gets cleaved by the cooperative actions of nucleolin and Drosha to an 80 nucleotide precursor 
reminiscent of precursor miRNA (156).  This product can be further processed by Dicer into 
a 22 nucleotide species, analogous to miRNA.  DGCR8 localizes primarily to the nucleolus 
and the dsRNA binding domains appear to be necessary for this since a truncation mutant 
lacking these domains is retained in the nucleus but fails to enter the nucleolus (81).  
Similarly, if the RNA recognition motifs (RRM) of nucleolin are deleted it fails to enter the 
nucleolus (168).  Nucleolar retention of nucleolin requires a minimum of two of the four 
RRM domains to be present.  It is possible that cytoplasmic localization of nucleolin does not 
60
account for the disruption of miRNA processing we observed in Fig. 5 but instead is the 
result of nucleolin leaving the nucleolus because of the induction of stress on the cell, which 
has been previously reported (164).  
 The domain structure of nucleolin includes an acidic N-terminal region followed by a 
NLS, four RNA recognition motifs, and an arginine-glycine rich repeat domain with putative 
RNA helicase activity (169).  The four RNA recognition motifs bind to rRNA in a stem-loop 
conformation stabilizing it for cleavage (169).  While the four RRM domains are sufficient 
for RNA binding, the acidic N-terminal domain is required for cleavage of the precursor 
rRNA in vitro indicating it may be necessary for interactions with other proteins in the 
complex (157).  Our data demonstrates that nucleolin interacts with DGCR8 and Drosha in 
an RNA-independent manner and yet also binds to the pri-miRNA.  Based on this, we 
propose that while nucleolin may not possess any RNase III domains characteristic of the 
core proteins in the miRNA biogenesis pathway (13, 170), it instead facilitates cleavage of 
the primary miRNA by maintaining proper conformation of the pri-miRNA while 
simultaneously positioning Drosha and DGCR8 for binding and cleavage. 
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Fig 12.  Model of the bipartite regulation of bcl-2 by nucleolin.
Under normal conditions nucleolin resides in the nucleus where it can bind with Drosha and 
DGCR8 to increase the processing of miR-15a and miR-16-1, which target BCL-2 mRNA 
for degradation.  However, upon induction of cellular stress, nucleolin moves from the 
nucleus to the cytoplasm where it binds to and stabilizes BCL-2 mRNA.  Simultaneously, 
there is less miR-15a and miR-16-1 due to reduced biogenesis in the absence of nuclear 
nucleolin.  This provides cells with multiple levels of control in their reaction to cellular 
stress.  
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Chapter 4: Identification of RRBP1 as a repressor of miR-200 biogenesis and a novel 
miRNA-mediated coherent feedforward loop.
4.1. Introduction
Zinc-finger enhancer binding (ZEB) transcription factors (ZEB1 and ZEB2) are critical 
mediators in the acquisition of stem-like characteristics of cancers.  Recently it was found 
that the histone methylation of H3K4 in the promoter region of ZEB1 is be found in a 
bivalent in plastic cancer cell populations allowing the conversion of non-stem like cells to a 
stem-like population thereby increasing tumorigenic and malignant potential (171).  The 
ZEB1/2 transcriptional repressors form a well-established feedback loop that inhibits the 
transcription of the miR-200 family (miR-200a/b/c, miR-141, and miR-429), which in turn 
inhibit the mRNA of ZEB1/2 (110, 111, 172).    
4.2. Results
4.2.1. TCGA analysis of miRNA in patients stratified by ZEB1/2 expression
We screened the TCGA breast cancer dataset using samples that had both RNAseq and 
miRNAseq (n=509) and separated stratified samples having high and low ZEB1/ZEB2 
expression.  There was a good correlation of ZEB1 and ZEB2 expression (Pearson 
correlation r=0.84), suggesting the expression of these molecules are under similar regulation 
(Fig. 13).  Therefore expression data from both molecules were used to separate samples into 
ZEB1/2 high and low groups.  There was no particular association of ZEB1/2 to any breast 
cancer subtypes.
63
 We identified the top differentially expressed miRNAs between the ZEB high/low 
groups and found 145 altered miRNA (Appendix table 1).  The expression of mature miRNA 
in the miR-200 family (miR-200a/b/c, miR-141, miR-429) was inversely correlated with 
ZEB1/2 as is expected due to the reciprocal feedback between the two (Fig. 13).  Since the 
regulation of ZEB1/2, and indeed all known mechanisms of miR-200 regulation are 
transcriptional in nature, we evaluated the expression of the primary miRNA and surprisingly 
saw that it did not correlate with mature miR-200 expression (Fig 14).  The levels of primary 
miR-200 family members remained constant between ZEB1/2 low compared to ZEB1/2 high 
samples.    
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Fig. 13. Correlation between miRNA in ZEB1/2 high and low patient samples
145 differentially expressed miRNAs were found in ZEB1/2 high vs low expressing samples 
that are shown on the heat map on the left (see Appendix for list of miRNAs).  The miR-200 
family (highlighted in yellow in heat map on the left) were compared to ZEB1/2 expression 
and found to be inversely proportional as existing models of ZEB1/2-miR-200 axis predict.
Fig. 14. Expression of pri-miR-200 vs. ZEB1/2 high and low patient datasets
Sequencing reads were mapped back to pri-miRNA sequences to quantify pri-miR-200 
family expression.  Some samples could not be mapped back (plotted along x-axis).  For all 
samples with pri-miR-200 reads, no significant correlation was found between ZEB1/2 
expression (low= green, high= pink) suggesting in patient samples the expression of pri-
miR-200 family is independent of ZEB1/2 expression.
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4.2.2. Analysis of pri- and mature miR-200 family in breast cancer cell lines
 We screened a panel of breast cancer cell lines for mature and primary miR-200 in an 
attempt to validate the TCGA data.  Consistent with the TCGA data, breast cancer cell lines 
separated by their miR-200 family expression showed an inverse correlation with ZEB1/2 
expression  (Fig. 15A,B) and yet the primary species of the miR-200 family did not 
recapitulate the mature miR-200 expression (Fig. 15C).  We also found no association with 
p53 expression, another established transcriptional regulator of miR-200 (173).  Included in 
the cell line panel are MCF-10A non-transformed mammary epithelial cells and 
MCF-10A.zeta cells overexpressing the protein 14-3-3ζ that we have previously to have high 
levels of ZEB1/2 due to activation of the TGF-β pathway (174).  
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Fig. 15. MiRNA and protein expression in breast cancer cell lines.
A) Breast cancer cell lines were separated by decreased mature miRNA expression.  
MCF-10A non-transformed cells used as a normal control while MCF-10A.zeta cells as a 
positive control for ZEB1/2 expression.  MiR-29c and U6 are controls for miRNA 
expression and loading, respectively. B) ZEB1 and ZEB2 expression is found only in 
mesenchymal breast cancer cell lines and correlations with mature miR-200 expression.  
There is no correlation between p53 expression and mature miR-200. C) Pri-miR-200b 
remains largely uncharged regardless of ZEB1/2 or p53 expression in breast cancer cell 
lines.   
 We used the MCF-10A and MCF-12A cell line models with or without 14-3-3ζ 
overexpression to interrogate possible mechanisms by which the miR-200 family may be 
post-transcriptionally regulated because 1) these cells displayed the largest difference 
between primary and mature miR-200 expression, and 2) to minimize the variability between 
cancer cell lines.  When examining the miR-200 family by northern blot we found there was 
no change in a precursor species despite loss of mature miRNA and simultaneously there was 
an excess of primary miR-200b in the cells with decreased mature miR-200b (Fig. 16).  The 
inverse correlation between primary miRNA and mature miRNA is indicative of processing 
defects while the unchanging levels of the precursor species suggested that pre- to mature 
miRNA processing may be the biogenesis stage being affected.  
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Fig 16. Loss of mature miR-200 expression does not alter pre-miR-200 levels and 
increases pri-miR-200.
The overexpression of 14-3-3ζ significantly reduces mature miR-200 expression in both 
MCF-10A and MCF-12A non-transformed cell lines.  The level of pre-miR-200b is 
indicated in the northern blot remains unaltered between high and low miR-200 
expression.  The pri-miR-200 levels significantly increase in cells with low expression of 
mature miR-200.
4.2.3. ZEB1/2 maintain transcriptional repression of the miR-200 family
 We sought to determine if the transcriptional repressors ZEB1/2 might fail to repress 
the miR-200b/a/429 cluster in the 10A.ζ overexpressing cells despite ZEB1/2 being 
expressed at high levels compared to vector control cells.  To test this we conducted a dual 
luciferase assay with the promoter region of the miR-200b/a/429 cluster containing the two 
E-boxes upstream of the transcriptional start site cloned upstream of firefly luciferase (Fig. 
17A).  As a control, an E-box mutant was included which was previously characterized as 
failing to be recognized by ZEB1/2 (111).  MCF-10A or MCF-12A vector controls cells or 
14-3-3ζ overexpressing cells were co-transfected with either the wild type or mutant 
promoter constructs along with Renilla luciferase.  As expected, we found the MCF-10A 
vector control cells had equal levels of expression between wild type and mutant constructs 
while the 14-3-3ζ overexpressing cells had a relative luminosity nearly equal to the empty 
luciferase plasmids due to repression from ZEB1/2 (Fig. 17B).  A similar case was found in 
the MCF-12A cells; however, the vector control cells with the E-box mutants exhibited 
higher relative luminosity compared to the wild type luciferase transfected cells.  This is 
likely because MCF-12A cells exhibit slightly more basal-like morphology due to higher 
ZEB1/2 levels.  When examining the luciferase signal from the E-box mutants in either the 
MCF-10A or 12A 14-3-3ζ overexpressing cells we found even the mutants were unable to 
restore the luciferase signal to that of their respective vector control cells.  We postulated this 
may be due to the fact 14-3-3ζ overexpressing cells have reduced p53 expression and since 
p53 is a positive regulator of miR-200 transcription the cells were unable to express an equal 
level of luciferase compared to vector controls.  To test this, we overexpressed p53 in the 
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14-3-3ζ overexpressing cells; however, we found this had no effect on luciferase expression.  
Nor did it have any impact on miR-200 expression, indicating loss of p53 was not 
responsible for low miR-200 expression in 14-3-3ζ overexpressing cells (Fig. 17D).  It is 
possible that another transcription factor is responsible for the failure of the E-box mutants to 
return to vector control cell luciferase levels. 
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Fig 17. ZEB1 and ZEB2 transcriptionally repress the miR-200b/a/429 promoter
A) Diagram of luciferase constructs with miR-200b/a/429 ZEB1/2 WT and mutant E-box 
binding sites listed.  B) Luminescence readings (normalized to Renilla) of 10A (left) and 
12A (right) cells with low or high 14-3-3 zeta.  The luciferase readings in zeta high cells 
are nearly the same as the empty vector indicating significant repression from ZEB1/2. C) 
Western blot demonstrating the exogenous rescue of p53 expression in 10A or 12A zeta.  
D) Northern blot of miR-200b and miR-29c in p53 rescued cells shows no change in 
expression of mir-200b. 
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4.2.4. TGF-β stimulation or p53 loss do not alter pri- or pre-miR-200 expression
 14-3-3ζ is a known activator of the TGF-β pathway and inhibitor of p53 expression 
via Akt phosphorylation of MDM2 (174, 175).  We sought to separate these pathways and 
examine their affect on miR-200 expression in the absence of 14-3-3ζ overexpression to 
determine if 14-3-3ζ may be playing a direct role in miR-200 regulation.  We treated 
MCF-12A cells with 5 ng/ml of TGF-β for two weeks, which was sufficient to induce an 
epithelial-to-mesenchymal transition (Fig. 18A).  After two weeks samples were either 
maintained in TGF-β or allowed to grow in its absence for an additional two weeks.  
Additionally, we generated MCF-12A cells stably expressing an p53-specific shRNA or a 
control shRNA to GFP (Fig. 18A).  The knockdown efficiency was greater than 90%, which 
reduced the cell levels of p53 to below that of 14-3-3ζ overexpressing cells.  We observed 
reduced miR-200 expression in the TGF-β-treated cells and the loss of expression was 
maintained following removal of TGF-β.  Loss of p53 had a similar level of decreased 
miR-200 (Fig. 18B).  MiR-29c was used as a control as it is known to increase in expression 
following EMT.  Consistent with previous observations, the precursor levels of the miR-200 
family were unaltered in the TGF-β-treated or p53 knockdown cells indicating the miR-200 
expression patterns associated with 14-3-3ζ overexpression were not due to 14-3-3ζ directly 
affecting miR-200 regulation.  More likely, the effects observed in 14-3-3ζ overexpressing 
cells are due to a combined effect from both the TGF-β pathways and loss of p53.  This also 
indicates that the post-transcriptional regulation of the miR-200 family is a common 
phenomenon and not specific to any particular stimulus. 
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Fig 18. TGF-beta treatment or p53 loss downregulate miR-200 post-transcriptionally
A) Bright field microscopy of MCF-12A cells with TGF-beta treatment or p53 loss (inset) 
that appear more spindle-shaped indicative of an EMT. B) Northern analysis of miR-200 
family expression.  Neither TGF-beta treatment nor p53 loss affects pre-miR-200 expression 
or pri-miR-200 expression (C).
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4.2.5. Knockdown of ZEB1/2 in 14-3-3ζ overexpressing cells
 We sought to determine if loss of ZEB1/2 in 14-3-3ζ cells would restore miR-200 
expression.  ZEB1 or ZEB2 were knocked down with siRNA either individually or 
simultaneously for 96 hours and miR-200 expression assessed by northern blot and qRT-
PCR.  In MCF-10A.ζ cells, siRNA treatment had no effect on miR-200b levels whatsoever 
(Fig. 19A,B).  Loss of either ZEB1 or ZEB2 in MCF-12A.ζ cells did not alter miR-200 
expression compared to a non-targeting control siRNA; however, the combined loss of both 
transcriptional repressors was able to slightly increase miR-200b expression.  Yet, the 
increase was unable to restore miR-200b levels of the vector control levels despite ZEB1 and 
ZEB2 being reduced to nearly equal levels (Fig. 19C).
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Fig. 19. Knockdown of ZEB1 and ZEB2 fails to restore miR-200 expression
A) qRT-PCR of miR-200 in MCF-10A (left) and MCF-12A (right) cells.  B) Northern 
analysis of miR-200b in knockdown cells. C) qRT-PCR of ZEB1/2 mRNA expression 
between 10A and 12A cells 96 hours after siRNA treatment. 
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4.2.6. Pre-miRNA levels remain unchanged in miR-200 low cells
  To this point we have demonstrated through patient data analysis, cell line studies, 
and genetic approaches that the miR-200 family is exhibits a high degree of post-
transcriptional control despite ZEB1/2 functioning to repress their transcription.  These 
claims are largely based on northern blot data, which shows the presence of distinct precursor 
bands corresponding to the individual miR-200 family members.  In an effort to rule out non-
specific hybridization, we fractionated the RNA from 10A.vec and 10A.ζ cells to isolate 
species less than 200 nucleotides using RNAzol.  This fraction should contain the precursor 
miRNA but exclude the much larger primary miRNA.  Successful fractionation was 
determined by northern blotting for miR-200b as shown in Fig. 20A.  The fractionated RNA, 
along with total RNA, was subjected to reverse transcription by random hexamers and pri 
and pre-miR-200b were quantified with specific primers to the stem-loop structure, which 
detects both pri and pre-miR-200b species.  In complete consistency with northern blot data, 
the small RNA fraction containing only the pre-miRNA showed no altered expression 
between 10A.vec and 10A.ζ cells while the total RNA fraction (containing both pri- and pre-
miRNA species) showed a significant increase of approximately 6 fold in 10A.zeta cells (Fig. 
20B).  The further assess if the LNA probes are detecting non-specific bands we synthesized 
an antisense RNA probe specific to the loop of miR-200b.  This region is distinct from the 
hybridization site of the LNA probe.  The cells in express an inducible miR-200b lentiviral 
construct that rapidly increase miR-200 levels in response to doxycycline to generate an 
otherwise hard to detect 60 nt Dicer substrate along with mature miR-200b expression.   The 
northern blots for the RNA loop probe and LNA probe are taken from the exact same 
79
membrane.  The membrane was hybridized using the RNA loop probe first, then stripped and 
re-exposed for 4 days to ensure that no residual signal remained, and then reprobed with the 
LNA to miR-200b (Fig. 20C).  These data indicated the precursor species detected by 
northern blot were real and not due to non-specific hybridization of the LNA probes.
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Fig. 20. Validation of miR-200 precursor
A) Validation of low molecular weight RNA fractionation by northern blot. B) qRT-PCR 
using either total RNA (white bars) or small RNA fraction (black bars) for pre-miR-200b.  
C) Northern blot for pre-miR-200b using an anti-sense RNA to the loop region (left) that 
binds a different region from the LNA probe (right).  The loop RNA probe fails to detect 
mature miR-200 but detects pre-miR-200b exactly as the LNA probe demonstrating the 
pre-miR-200b signal is not an artifact of hybridization
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 We went on to access the validity of the pri-miRNA northern blot signal for possible 
non-specific hybridization.  As described in section 1.1 pri-miRNA are transcribed by RNA 
pol II that results in the addition of a poly(A) tail.  We isolated poly(A)+ RNA by oligo-dT 
bead capture and analyzed the expression of pri-miR-200 by northern blot and qRT-PCR.  
Interestingly, northern blot analysis of poly(A)+ RNA showed no significant differences 
between 10A.vec and 10A.ζ cells (Fig. 21A).  These results were also confirmed by qRT-
PCR for pri-miR-200b, yet total RNA showed increased pri-miR-200b (Fig. 21B, Fig 20B).  
This indicates the poly-adenylated pri-miRNA is likely rapidly cleaved by Drosha, at which 
point the poly(A)+ tail is cleaved.  The overall abundance of poly(A)+ pri-miRNA was also 
significantly lower in its northern blot signal suggesting the cleavage occurs quickly and the 
poly(A)+ pri-miR-200 family represents only a small minority of the total pri-miRNA signal 
detected from total RNA.  These findings are consistent with the observation that Drosha 
cleavage occurs co-transcriptionally (23).
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Fig. 21. Poly-(A)+ selected RNA northern blot and qRT-PCR
A) Pri-miR-200 family expression was analyzed in poly-(A)+ selected RNA and showed no 
difference in expression.  B) Confirmation of northern data by qRT-PCR of pri-miR-200b.
4.2.7. Re-expression of miR-200 clusters         
 We have demonstrated through multiple independent assays that the miR-200 family 
is under negative post-transcriptional control and this is a common feature amongst various 
methods known to induce loss of miR-200.  
 To ascertain if the loss of miR-200 is due to the loss of an activator of miRNA 
processing or the gain of an inhibitor, we transduced MCF-10A.vec and MCF-10A.ζ cells 
with two lentiviruses expressing either the miR-200b/200a/429 cluster or the miR-200c/141 
cluster as they exist in their respective genomic context.  We postulated that if there were a 
loss of an activator of miR-200 processing then regardless of the amount of upstream 
miRNA put into the cells, the mature miRNA would fail to be generated in the 14-3-3ζ 
overexpressing cells.  We observed that the miRNA were readily processed in both the vector 
and the zeta overexpressing cells (Fig. 22C).  This implied that 14-3-3ζ cells possessed a 
repressor of biogenesis that could be titrated away with sufficient quantities of primary 
miRNA allowing the remaining, uninhibited miRNAs to be recognized by the biogenesis 
machinery and generate the mature species.  In addition to this; however, we found when one 
cluster was overexpressed (e.g. miR-200b/a/429), the miRNA from the other cluster (i.e. 
miR-200c/141) also increased to an equal level.  This could be explained with the feedback 
between miR-200 and ZEB1/2 where high levels of miR-200b/a/429 inhibit ZEB1/2, which 
de-represses the endogenous promoter for miR-200c/141.  However, after examining the 
ZEB1/2 levels by western blot and qRT-PCR we found the levels of ZEB1/2 are not restored 
to the levels of the 10A.vec cells (Fig. 22D,E).  The lack of full ZEB1/2 restoration is also 
exemplified by E-cadherin expression, which is directly transcriptionally inhibited by 
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ZEB1/2.  E-cadherin the 10A.ζ cells overexpressing either cluster is not fully restored to the 
level of 10A.vec cells.  Additionally, the increase between the exogenous and endogenous 
cluster expression was equal.  The only exception to this was miR-429, which was only 
increased in cells expressing the exogenous miR-200b/a/429 cluster but not the miR-200c/
141 cluster (Fig. 22C).  
 Another possible explanation lies in the sequence similarity between the various 
mature species.  MiR-200b and miR-200c are identical except for two residues as are 
miR-200a and miR-141.  Highly similar mature miRNA (Fig. 22A) with the potential to cross 
react to the northern probes exist on either cluster, despite locked nucleic acids being 
exquisitely specific.  To rule out cross reactivity of probes we synthesized a series of spike-in 
miRNAs to specific to miR-200a, b, or c along with 8 nucleotides of their flanking 
nucleotides.  The amount of spike-in RNA roughly equivalent to twice that of the levels 
present in 10A.vec cells and optimized hybridization and washing conditions were 
determined by titrating the spike-in RNAs with and comparing to the expression in 10A.vec 
cells (Fig. 22B).  When these same conditions were applied to the northern blots of the 
miR-200 cluster expressing clones it is clear that the increase of non-cluster expressed 
miRNA is not due to cross reactivity.
 Taken together, this suggests that miR-200 repression is due to the presence of an 
inhibitor and not the absence of an activator of miRNA biogenesis.  More importantly, our 
data suggests that the individual miR-200 family members may be able to ‘communicate’ 
with one another as to their expression levels through titrating away the repressor protein(s).  
However, this may not be the case for miR-429 since overexpression of the miR-200c/141 
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cluster did not upregulate its expression beyond that of the 10A.vec cells, which is expected 
due to the loss of ZEB1/2.
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Fig. 22. Re-expression of miR-200 clusters induces upregulation endogenous cluster 
independent of transcription.
A) Sequence similarity between the miR-200 family members.  MiR-200a and miR-141 
differ in two nucleotides, as do mir-200b and mir-200c, while mir-429 is the most 
divergent from the others. B) Optimization of northern stringency to distinguish closely 
related miR-200 family members.  Synthetic RNAs were spiked-in at varying 
concentration to detect cross-hybridization. C) Re-expression of miR-200 family clusters 
as they exist in a genomic context with spike-in RNAs to rule determine specificity.  D) 
Western blot analysis of miR-200 cluster re-expressed cells.  E-cadherin is a direct target of 
ZEB1 while vimentin is not but remains a marker of mesenchymal cells.  E) qRT-PCR 
analysis of ZEB1 expression in cluster re-expressed cells.  
4.2.8. Coherent feedforward regulation of miR-200 biogenesis
 The results of the miR-200 cluster expression indicate that a level of crosstalk exists 
between the miR-200 species.  However, accurate dissection of this is complicated by the 
fact these miRNAs are stably expressed for an extended period of time before analyzing 
expression patterns and the contribution of individual miR-200 species cannot be separated 
from the others in the cluster.  In an effort to obtain more specific details of the timing and 
contribution of individual miR-200 family members we cloned individual pri-miR-200 
members into the pTRIPz doxycycline-inducible lentiviral plasmid.  Each pri-miRNA was 
cloned with 50 nucleotides of flanking regions to the hairpin to include any cis acting 
sequences (10).  MCF-10A.ζ cells were transduced with lentiviruses expressing the inducible 
constructs because they contain very low levels of endogenous miR-200 allowing accurate 
quantification and visualization by northern blot of the miRNA increase as a result of 
doxycycline induction.  Following a timecourse induction with pri-miR-200b over 24 hours, 
qRT-PCR analysis showed a nice correlation between the expression of pri-miR-200b and 
mature miR-200b (Fig 23A).  There is a slight delay in the mature species from the primary, 
which is likely due time necessary for processing by the microprocessor and Dicer.  
 When MCF-10Aζ cells with inducible miR-200c were induced over a 24 hour 
timecourse an ~25-fold increase in mature miR-200c was detected at 4 hours increasing to an 
80-fold increase by 24 hours (Fig 23B).  An analysis of mature miR-200b along the same 
timecourse revealed an ~20-fold increase by 4 hours, which plateaued at 8 hours after 
induction.  This indicated that upregulation of miR-200c alone can induce the post-
transcriptional upregulation of miR-200b at time points too early for a feedback inhibition to 
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occur with ZEB1/2.  Indeed, when ZEB1/2 mRNA was analyzed along the same timecourse 
there was no significant change in expression (Fig. 23C).
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Fig. 23. Time course dependent induction of individual miR-200 members 
upregulates other members independent of transcription.
A) Timecourse of miR-200b induction determined by qRT-PCR.  Mature miR-200b 
induction (black bars) lags slightly behind pri-mir-200b induction (grey bars).  B) 
Induction of mir-200c (green bars) induces the expression of mature miR-200b (blue 
bars). C) ZEB1 (left) and ZEB2 (right) mRNA expression comparing 10A.vec cells with 
miR-200c induction and a control shRNA induction timecourse.
 To evaluate this effect under the most stringent conditions we decreased the time of 
induction to time points at 1, 2, 4, 6, and 8 hours and analyzed the increased expression by 
high stringency northern blotting with miR-200 spike-in RNAs to rule out cross reactivity.  In 
addition to the inducible pri-miR-200 members, we also included a non-targeting inducible 
shRNA, which still requires processing by Drosha and Dicer to rule out the effects of 
doxycycline or increased processing load on the biogenesis machinery.  We ruled out 
feedback from ZEB1 by evaluating its expression via western blot at each time point and for 
each individual miR-200-inducible clone (Fig. 24).  MCF-10A.vec cells were included as a 
control to determine physiological levels of miR-200 family members.  MiR-29c was 
included as a control to rule out the possibility that miRNA expression is being globally 
regulated.  Lastly, whenever possible, the same membrane was used to probe all miRNAs to 
reduce any variability in loading or transferring.  MiR-429 is not included in the analysis 
because its expression was undetectable in all cases due to extremely low expression.
 Induction of miR-200a caused the coordinated upregulation of both miR-200b and 
miR-141 but failed to induce miR-200c (Fig. 25).  Evidence of post-transcriptional 
biogenesis of miR-200b and miR-141 is additionally evident due to the appearance of a 60 nt 
band corresponding to the Dicer substrate precursor.  MiR-200b induction only caused the 
upregulation of miR-200c (Fig. 26) and, conversely, the induction of miR-200c only 
upregulated miR-200b (Fig. 27).  As expected, inducing the control shRNA failed to induce 
the expression of any of the miR-200 family members (Fig. 28). 
 The data presented from the miR-200 clusters and inducible systems clearly 
demonstrates a post-transcriptional upregulation of miR-200 biogenesis wherein individual 
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species crosstalk with one another to titrate away the effects of a repressor.  This represents 
the first time miRNAs have been shown to regulate one another through a mechanism 
independent feedback involving proteins.         
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Fig. 24. ZEB1 expression in each of the miR-200 expressing clones during induction 
timecourse.
Each of the miR-200 expressing clones were induced with doxycycline over an 8 hour 
timecourse to evaluate the expression of ZEB1 expression.  Samples are compared to 
10A.vec with low ZEB1 expression and high mir-200 expression.
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Fig. 25. Co-upregulation of miRNA following miR-200a induction
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Fig. 26. Co-upregulation of miRNA following miR-200b induction
Fig. 25. Co-upregulation of miRNA following miR-200b induction
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Fig. 27. Co-upregulation of miRNA following miR-200c induction
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Fig. 28. Co-upregulation of miRNA following induction of a non-targeting shRNA
4.2.9. Development of Cross-linking and PNA Pulldown (CLaPP) assay
 To identify what protein(s) may be responsible for inhibition we first attempted a 
standard RNA pulldown assay with in vitro transcribed biotinylated precursor miRNAs and 
identified many known RNA binding proteins by mass spectrometry yet functional analysis 
revealed these were all non-specific binders.  Therefore, we sought to develop a new 
technique in which we could specifically capture the endogenous precursor miRNA in a cell 
after photocrosslinking to create a covalent bond between protein and RNA.  Similar 
approaches have been taken to capture proteins bound to all polyadenylated RNAs using an 
Oligo-dT capture probe (139, 140, 176) but this lacks specificity and precursor miRNA do 
not possess a poly(A) tail.  Specific capture of nucleic acids has been performed using 
biotinylated antisense RNA probes but to achieve the necessary specificity the antisense 
probes must be at least 150 nucleotides in length, which is longer than the length of the entire 
precursor (143).  Instead we chose to design antisense peptide nucleic acid (PNA) probes 
because of their strand invasive potential to disrupt the precursor miRNA stem-loop structure 
and because of a high level of specificity achieved with only 15 nucleotides (144, 177–181).  
Furthermore, since PNAs contain an amino acid backbone and not a negatively charged sugar 
phosphate backbone their hybridization efficiency is independent of the ionic strength of the 
hybridization buffer.  We designed 15-mer antisense PNAs to the 3’ tail of the miR-200 
precursor, which were long enough to specifically recognize individual miRNA precursors 
but short enough to minimally disrupt the endogenous protein-RNA interactions (Table 1).  
Importantly, their hybridization temperatures (Tm) were approximately 30°C above that for 
RNAs with the same sequences under the same conditions (Table 2).
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Table 2. Comparison of hybridization temperatures for PNAs and RNAs 
with the same base sequence.
Table 1. Antisense PNA sequences used in CLaPP assay
 We first sought to determine the sensitivity and specificity with which we can capture 
the precursor miRNAs.  In vitro transcribed precursor miRNAs (miR-200a, b, c, and 29c) 
corresponding to the sequences in miRbase were PAGE purified and mixed.  The mixed oligo 
pool was divided equally six ways.  One sample was used as an input control, aliquot for 
each of the four PNAs, and one aliquot was mixed with magnetic streptavidin beads only 
(Fig 29).  For binding and washing conditions see materials and methods.  100 pmol of PNA 
was used per reaction and ~20 pmol of each pre-miRNA was present in the reaction giving a 
5-fold excess of PNA.  After hybridization, streptavidin capture, and washing, the RNA was 
eluted in formamide loading buffer by heating to 80°C for 5 minutes.  The supernatants after 
the initial capture were ethanol precipitated to determine sensitivity.  Input RNA, eluted 
RNA, and precipitated supernatants were analyzed by staining with SYBR gold II and by 
northern blotting.  Interestingly, in each of the PNA capture lanes a doublet band appears 
where the lower band represents free RNA and the upper band is the PNA-RNA hybrid 
indicating the PNA-RNA interaction remains so tightly bound that even under denaturing 
conditions the two remain hybridized.  Additionally, the PNA was able to specifically 
distinguish between miR-200b and miR-200c while the LNA probe was unable to do so 
under the most stringency of hybridization conditions, again validating the specificity of 
PNAs over other nucleic acid capture techniques.  
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Fig. 29. Specific capture and detection of pre-miR-200 sequences with antisense PNAs
The top panel is SYBR gold II staining of RNA.  Northern analysis was performed to 
specifically detect captured probes and supernatant as labeled.  MiR-200b and miR-200c 
were unable to be distinguished by the LNA probe due to the high concentration of present 
in each lane.
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Fig. 30. An overview of the CLaPP assay
Cells are first incubated with 4-thiouridine overnight and crosslinked with UV-C.  After 
lysing the cells under denaturing conditions the PNAs are incubated to hybridize to their 
targets at 55C.  After returning to room temperature, streptavidin beads are added to 
capture the PNA probes.  Beads are extensively washed under denaturing conditions and 
digested with an RNase cocktail to release proteins for identification by gel extraction and 
mass spectrometry. 
4.2.10. Identification of RRBP1 by CLaPP       
 To identify differential proteins bound to the miR-200 precursors we incubated 
MCF-12A.vec or MCF-12A.ζ cells in the presence of 100 µM 4-thiouridine for 24 hours 
followed by crosslinking RNAs to proteins by UVC (see methods).  Cell lysates were 
incubated with antisense PNAs to specific miR-200 precursors, extensively washed, and 
proteins were eluted by RNase treatment (Fig. 30).  
 We found one protein band in MCF-12A.ζ samples that was only identified in 
miR-200a/b/c antisense PNAs but not miR-29c antisense PNA (Fig. 31).  The band in 
question was identified by mass spectrometry to be Receptor of Ribosome Binding Protein 1 
(RRBP1).
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Fig. 31. Coomassie stain of gel after PNA capture
Lanes are marked with the specific antisense PNA used in the capture.  Highlighted region 
indicates bands identified by mass spectrometry as RRBP1
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 RRBP1 was originally identified as ES/130 for the polyclonal antibody used to detect 
it (ES) and its molecular weight in chicken embryonic cardiocytes (130 kDa) (182).  
Interestingly, it was found to be necessary for transitioning the cells from epithelial to 
mesenchymal during heart development.  Later studies established that RRBP1 expression is 
not limited to cardiac development but also necessary for development of the limb bud 
ectoderm, gut, and notochord suggesting widespread importance for embryogenesis (183).  
The first evidence of RRBP1 existing in human cells mapped its chromosomal location to 
20p12 (184).  The human homologue contains two distinct isoforms, a 180 kDa isoform 
which contains a decapeptide repeat of NQGKKAEGAQ repeated 54 times at its C-terminus 
and a 130 kDa isoform lacking the repeat region.  The decapeptide repeat region was found 
to be responsible for binding to ribosomes in the endoplasmic reticulum (185, 186) and 
RRBP1 assembles polysomes in the ER via its coiled-coil domain (187).  Overexpression of 
RRBP1 induces an elongated spindle shape in HeLa cells due to a microtubule binding 
region that functions to connect the endoplasmic reticulum to the microtubule network (151).  
Intestinal crypt stem cells were recently found to contain high levels of RRBP1 compared to 
the differentiated villus cells suggesting a role of RRBP1 in maintaining stemness in adult 
tissues (188).  Staining of breast cancer patients’ tissue samples revealed an extremely high 
number of samples (84%, 177/219) had overexpression of RRBP1 (189).  Additionally, 
RRBP1 was found to be overexpressed in lung cancer patients where it serves to protect the 
cancer cells from apoptosis induced by the unfolded protein response (UPR).  Induction of 
the UPR in mammary tissues was recently found to promote a stem-like population of 
CD44high/CD24low cells, which are known to have low levels of miR-200 (190, 191).    
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Fig. 32. Overview of RRBP1 domain structure. 
RRBP1 consists of a transmembrane domain at the N-terminus (purple) a decapeptide repeat 
necessary for binding to ribosomes, and a coiled coil domain that interacts with 
microtubules.  RRBP1 is expressed as two isoforms, a p180 isoform as drawn and a p130 
isoform that lacks the decapeptide repeat region
4.2.11. Characterization of RRBP1 as a repressor of miR-200 biogenesis  
 In our CLaPP assay RRBP1 was associated only with pre-miR-200 family members 
and only in cells with low levels of mature miR-200 suggesting it may be necessary for 
repressing their biogenesis.  We first evaluated RRBP1 expression in the breast cancer cell 
lines described in Fig. 15.  There was a nearly perfect inverse correlation between RRBP1 
expression and mature miR-200 expression in these cells (Fig. 33).  This was excellent 
correlative data; however, to establish a causal role for RRBP1 in miR-200 repression we 
exogenously expressed either the p130 or p180 isoforms in MCF-10A cells.  Expression 
levels were within physiological levels observed in basal-like breast cancer cells (Fig. 34A).  
Expression of both isoforms induced an EMT in the MCF-10A cells.  Northern blot and qRT-
PCR analysis of miR-200 levels revealed exogenous expression reduced mature levels to 
approximately 20% the levels of vector control cells (Fig. 34B,C).  The most striking 
evidence that RRBP1 overexpression is the cause of miR-200 biogenesis defects was in 
analyzing the pri-miR-200 levels.  Exogenously expressed RRBP1 isoforms induced an 
upregulation of pri-miR-200b and -200c while pri-miR-200a remained unchanged, exactly 
recapitulated the alterations in pri-miRNA observed with overexpression of 14-3-3ζ  (Fig. 
34D).  RRBP1 shRNA loss-of-function studies revealed a slight, but consistent increase in 
miR-200 expression in both the MCF-10A and MCF-12A cell lines (Fig. 35C,D).    
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Fig. 33. RRBP1 expression in breast cancer cell line panel
RRBP1 expression was analyzed in the context of the breast cancer cell line panel as before 
(Fig 14).  A strong inverse correlation exists between mature mir-200 family members and 
RRBP1.
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Fig. 34. Gain-of-function analysis of RRBP1 on miR-200 expression
A) RRBP1 was expressed as two different isoforms, p130 or p180. B) qRT-PCR analysis 
of miR-200 mature expression in RRBP1 overexpressing cells. C) Northern analysis of 
mir-200 in RRBP1 overexpressing cells. D) Pri-miR-200a, 200b, and 200c expression.
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Fig. 35. Knockdown of RRBP1 increases miR-200 expression
A) Knockdown of RRBP1 using two different shRNA clones in MCF-10A cells. B) 
Knockdown efficiency in MCF-12A cells. C) qRT-PCR analysis of mature miR-200 in 
MCF-10A knockdown cells. D) qRT-PCR analysis of mature miR-200 in MCF-12A 
knockdown cells.
4.2.12. TGF-β induces expression of RRBP1
 TGF-β is one of the best-characterized inducers of mir-200 loss (110).  We asked 
whether TGF-β has any effect on RRBP1 expression.  To test this, we treated MCF-10A cells 
with 5 ng/ml TGF-β and monitored RRBP1 expression by both western blot and qRT-PCR 
(Fig. 36A,B).  Protein levels of RRBP1 significantly increased at 24 and 48 hours following 
treatment with TGF-β in addition to the appearance of the p130 isoform, which is 
undetectable in unstimulated cells.  RRBP1 mRNA levels also increase ~4-fold suggesting 
transcriptional activation may be responsible for the activation (Fig. 36B).  As expected, 
there was a decrease in the expression of miR-200b, which was inversely proportional to the 
level of RRBP1 (Fig. 36C).
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Fig. 36. TGF-beta treatment induces RRBP1 expression
A) MCF-10A cells were treated with 5 ng/ml of TGF-beta for 24 or 48 hours and 
protein expression determined by western blot. B) mRNA expression of RRBP1 
following TGF-beta treatment C) Northern analysis confirming the loss of miR-200b 
with the increase in RRBP1.
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4.2.13. Characterizing RRBP1 binding to miR-200 by iCLIP
 RRBP1 consistently displayed an inverse correlation with miR-200 in cell lines, 
exogenous expression, and knockdown cells.  Additionally, we identified RRBP1 by 
capturing the precursor miR-200 family members via CLaPP assay under highly stringent 
conditions implicating its direct binding to the miR-200 precursors.  To exhaustively link 
RRBP1 as a direct repressor of miR-200 biogenesis we sought to characterize its binding by 
conducting an individual nucleotide Crosslinking and Immunoprecipitation assay (iCLIP).  
We first optimized crosslinking conditions for p130 and p180 isoforms after incubating with 
4-thiouridine and crosslinking with UV365.  FLAG-tagged DGCR8 was included as a control 
during optimization steps.  Crosslinking of RRBP1 to RNA was apparent even by western 
blotting, which caused a shifted species to be detected (Fig. 37).  We also observed that high 
levels of p180 get post-translationally cleaved into p130.  To assess specificity of binding, 
samples were treated with a low dilution of RNase I (1:50), in which the crosslinked protein-
RNA hybrids migrate at approximately 5 kDa above the non-crosslinked protein instead of 
forming a diffuse slow migrating band (192).  We found the p130 isoform was the dominant 
isoform responsible for RNA-binding as most of the RNA from the p180-expressing cells 
migrated with that isoform (Fig. 38A).  RRBP1 also appears to be a robust RNA-binding 
protein since RNA remained bound to RRBP1 in the presence of 1 molar NaCl while no 
RNA was detected in the uncrosslinked DGCR8 lane.  This was overcome by treating 
immunoprecipitated RRBP1 with a 7M urea solution, diluting the eluate, and 
immunoprecipitating again.  Optimal RNase concentrations were determined by a dilution 
series of RNase I on the crosslinked p130 isoform (Fig. 38B).  A dilution of 1:250 of RNase I 
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was found to be optimal.  Each isoform of RRBP1 was immunoprecipitated in triplicate as 
well as three negative controls of untransfected cells and uncrosslinked p130 and p180 (Fig. 
39).  Each replicate, including negative controls was individually barcoded to trace back 
sequences to individual replicates following next generation sequencing.
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Fig. 37. Expression validation of RRBP1 clones for iCLIP
Western blot analysis of FLAG in cells without transfection (first lane), and with 
p130 and p180 expression plus or minutes UV crosslinking (lanes 2-5) and DGCR8 
serving as a positive control (last two lanes).  The two images are the same 
membrane at different exposures.
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Fig. 38. Optimization of crosslinking conditions for RRBP1
A) FLAG-tagged RRBP1 or DGCR8 was immunoprecipitated following extensive 
RNase I digestion to determine specificity of the crosslink.  B) Dilution series of 
RNase I on the p130 isoform to obtain optimal RNA fragmentation.
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Fig 39. Triplicate iCLIP analysis of p130 and p180 isoforms
Using the optimized conditions determined in Fig 36, the p130 and p180 isoforms 
were immunoprecipitated in triplicate along with three negative control experiments.
 Library preparation optimization was done with low, medium, and high eluates (see 
methods) to determine the optimal cycle numbers to amplify libraries without inducing non-
specific amplification.  There was no detectable signal in the non-transfected negative control 
library, as expected, while the p130 and p180 uncrosslinked samples had a minimal 
detectable signal (Fig. 40).  This is likely due to residual RNA binding given the 
aforementioned robustness of RRBP1.  Specific crosslinked immunoprecipitations of both 
p130 and p180 isoforms resulted in strong signals compared to negative controls.  The 
optimal cycle numbers were used for preparative scale library amplification.  The individual 
libraries were pooled, gel-purified, and precipitated for next-gen sequencing by Illumina 
HiSeq 2500 50-nt single read sequencing.  
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Fig. 40. Library amplification of RRBP1-bound RNA
cDNAs were gel extracted in low, middle, and high sizes (see methods) and optimal 
amplification conditions for each was determined A) p130, B) p180, C) 
uncrosslinked pooled p130 and p180, D) No trafection of RRBP1
4.2.14. Detection of pre-miRNA sequences in iCLIP libraries by PCR
 Before samples were pooled for next-gen sequencing, aliquots were analyzed by 
endpoint PCR to detect the presence or absence of precursor miRNA species.  Primers 
specific for the precursors of miR-200a, miR-200b, and miR-29c were used and a plasmid 
containing miR-200a and -200b sequences (b/a/429+Ctrl) or a PCR amplicon of pri-miR-29c 
from genomic DNA were used for specificity (Fig. 41).  The precursor for miR-200b was 
detected in high abundance in the p130-low library while it was detected in the p180-low/
med/high libraries but in lower abundance than the p130-low library.  No detection of pre-
miR-200b was observed in the negative control libraries.  Additionally, there was no signal 
detected for pre-miR-200a in any of the libraries while the positive control gave a clear 
signal.  This may indicate that RRBP1 does not bind to the precursor of miR-200a or may 
simply be that the region in which it binds is outside of the primers used to detect pre-
miR-200a.  Ultimately, the next-gen sequencing results will determine exactly what 
sequences are bound by RRBP1.  Similar to pre-miR-200a, we observed no signal in the 
libraries when pre-mir-29c was amplified.  This result is expected since capture of pre-
miR-29c by CLaPP assay did not return peptides to corresponding to RRBP1. 
 When the analysis of the iCLIP data and the CLaPP data are taken together, we can 
conclude that RRBP1 does directly bind to at least a portion of the miR-200 family members. 
Capture of pre-miR-200a by CLaPP did return RRBP1 peptides by mass spectrometry; 
however, it is possible that RRBP1 does not bind near the miR-200a stem-loop but rather 
binds to the pri-miR-200b/a/429 transcript and the anti-sense PNA captured the entire pri-
miRNA thus returning peptide hits by mass spectrometry. 
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Fig. 41. Detection of pre-miR-200 family members from iCLIP library
Amplified iCLIP libraries were subjected to endpoint PCR analysis using primers 
specific to the precursors of miR-200a (top), miR-200b (middle), or miR-29c 
(bottom).  Plasmids and PCR products for miR-200b/a/429 and pri-miR-29c, 
respectively were used as positive controls.
4.3. Discussion
 There are many molecular events that can independently lead to EMT in cells, yet all 
result in the loss of miR-200 (172, 193).  The ZEB1/2-miR-200 double negative feedback 
loop has been extensively described in the literature (110, 111, 194–198) yet analysis of 
patient data from TCGA indicates the a stronger correlation between miR-200 repressing 
ZEB1/2 than the inverse.  We validated this phenomenon in breast cancer cell lines and found 
it to support the TCGA data.  Our analysis, as well as others, of ZEB1/2 inhibition on the 
miR-200b/a/429 promoter by dual luciferase assay does support the repressive role of 
ZEB1/2; however, we found blockage of downstream processing of the miR-200 family 
resulted in large pools of unprocessed primary miRNA.  To reconcile these differences we 
propose that transcription of the miR-200 family may be greatly reduced in cells expressing 
high levels of ZEB1/2 but the inability of the cell to process existing pri-miR-200 pools, in 
addition to transcriptional ‘leakiness’ results in the observed counter-intuitive increased 
expression. 
 We uncovered a novel feedforward mechanism that exists between the different 
species of the miR-200 family.  In principle it is very similar to the ceRNA hypothesis, which 
postulates that upregulates of a mRNA targeted by a particular miRNA will ‘sponge’ away 
that miRNA resulting in increased expression of other mRNAs targeted by the same miRNA 
(113).  The difference in this instance is that one miRNA within the family can upregulate the 
other miRNAs in the family by titrating away a common repressor in RRBP1 (Fig. 42).  In 
this way, cells are able to insure the expression of all miR-200 family members equally.  We 
propose this miRNA-mediated miRNA upregulation may not be unique to the miR-200 
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cluster and may exist for other clusters containing miRNAs with highly similar sequences.  
Additionally, RRBP1 may not function solely as a repressor of the miR-200 family and may, 
in fact, exert broad influences on other miRNA species.  RRBP1 may also recruit specific 
mRNAs to the ER to activate or inhibit their translation, which is a known function of 
RRBP1.  If this is true, it would be interesting to see if the mRNAs and miRNAs bound by 
RRBP1 can be functionally classified into distinct classes such as a ‘pro-EMT’ or ‘pro-MET’ 
signature.  These hypotheses are testable from the data retrieved from the iCLIP of RRBP1.  
 In this study we developed a novel technique for capturing endogenous protein-RNA 
interactions using peptide nucleic acids.  Our technique, termed CLaPP, offer significant 
advantages to existing methods of identifying proteins bound to specific RNA species.  First, 
our technique targets specific RNA species instead of relying on global analyses from poly-
(A)+ selection.  Second, the uncharged peptide backbone of the PNA facilitates strand 
invasion and displacement of highly structured RNAs under low salt condition.  Others have 
avoided this problem by generating tiling arrays to different parts of the target mRNA to 
avoid failed detection in structured region (142, 143).  However, this is often not possible in 
the case of miRNA given their short length.  Third, while not employed in this study, PNAs 
can be easily modified to cross the cell membrane in a transfection-free system.  It is possible 
that one could capture target RNAs before cellular lysis or even inject into an animal to 
capture the repertoire of RNA-binding proteins in tumor models or during different 
developmental stages.  
 In conclusion, we developed a highly sensitive assay to capture endogenous protein-
RNA interactions to identify RRBP1 as a novel repressor of miRNA synthesis, which 
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allowed characterization for the first time of a miRNA-mediated post-transcriptional 
feedforward loop. 
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Fig. 42. Model of RRBP1 regulation of miR-200 in luminal and basal-like breast 
cancers. In luminal breast cancers RRBP1 expression remains low facilitating the 
biogenesis of the miR-200 family to maintain a more epithelial phenotype.  RRBP1 
expression in basal-like breast cancers is increased resulting in reduced conversion of pre-
miRNA to mature miRNA and a more mesenchymal phenotype.
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Fig. 43. Model of repressor titrating miRNA upregulation. Under conditions where 
RRBP1 expression is high, processing of the miR-200 family is repressed.  However, 
upregulation of any one member or cluster results in saturation of the repressing ability of 
RRBP1 and allows the expression of the mature form of all miR-200 members to increase.
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Fig. 44. TGF-beta-induced loss of miR-200 expression via multiple mechanisms.  
Established models of TGF-beta treatment involve the upregulation of ZEB1/2 following 
TGF-beta treatment via transcriptional activation by SMAD2/3.  ZEB1/2 transcriptionally 
repress the miR-200b/a/429 and miR-200c/141 clusters.  Simultaneously, TGF-beta 
treatment induces the expression of RRBP1 at the mRNA and protein level, which binds to 
the miR-200 precursors to prevent their processing to mature miRNA.  The reduced levels 
of mature miR-200 can no longer repress the mRNA of ZEB1/2 resulting in further 
transcriptional repression of the miR-200 clusters.  
Chapter 5: Summary and Future Directions
5.1. Summary
 The research presented herein identifies and characterizes two ribosome interacting 
proteins in nucleolin and RRBP1 as key accessory proteins for microRNA biogenesis.  Each 
forms unique feedback mechanisms via regulating miRNA.  Nucleolin is a protein able to 
shuttle in and out of the nucleus.  While in the nucleus it interacts with the microprocessor 
complex and directs the biogenesis of miR-15a/16-1 that downregulates the mRNA of bcl-2.  
When nucleolin shuttles to the cytoplasm upon induction of cellular stress, it stabilizes the 
mRNA of bcl-2 by binding the 3’UTR while simultaneously reducing the abundance of 
miR-15a/16-1, further increasing bcl-2 mRNA stability.  When considered in the context of 
cancer, in which nucleolin is often found in the cytoplasm (158), cancer cells are able to 
inhibit apoptosis efficiently by compartmentalizing the various functions of nucleolin. While 
not analyzed in this study, previous reports of the binding sites for nucleolin and miR-15a/
16-1 do not overlap indicating that nucleolin is not stabilizing bcl-2 by occupying miRNA 
binding sites.
 Nucleolin has garnered attention from drug developers because it is often found on 
the surface of cancer cells, as a result of phosphorylation by Akt, and surface localization 
correlates with metastatic potential (199, 200).  One unique function of nucleolin is an ability 
to tightly bind G-quadruplex DNA structures, which are formed by repetitive sequences of 
guanosines forming a planar surface (162, 201).  A G-quadruplex forming oligonucleotide 
called AS1411 was specifically designed to bind surface expressed nucleolin causing its 
internalization (202).  Indeed, targeting nucleolin in breast cancer using AS1411 was shown 
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to inhibit tumor proliferation in vivo (203).  Since G-quadruplexes are extraordinarily stable 
and cheap to produce, drugs like AS1411 represent an alternative to small molecule therapies 
and may have reduced chances for drug resistance due to the wide net of genes targeted by 
altering miRNA biogenesis.          
 Through mining TCGA data, we observed a disconnect between what is known 
regarding the regulation of the miR-200 family and their expression patterns in patient data.  
After extensively validating the presence of primary and precursor miR-200 in cells failing to 
express the mature species we concluded a repressor complex must be present.  Re-
expressing the miRNA-200 clusters revealed they possess the ability to upregulate one 
another in a manner independent of known feedback transcriptional loops.  This observation 
is similar in principle to a proposed model of sponging RNAs also called competing 
endogenous RNAs (113).  This hypothesis states that two different RNAs targeted by the 
same miRNAs can coherently alter the expression of each other through up- or down-
regulation of one of the RNA species.  For example, upregulation of one species would be 
bound by a greater proportion of the miRNA pool resulting in depression of the second 
mRNA, thus as mRNA X increases so does mRNA Y and vice versa.  The hypothesis 
proposed in this study is similar except that the miRNA is not the repressor; rather it is the 
repressed RNA species with a protein component as a repressor.  We demonstrated that 
miR-200b can post-transcriptionally upregulate the expression of miR-200c through titrating 
away RRBP1 as a repressor.  Similarly, miR-200a can post-transcriptionally upregulate 
miR-141 and miR-200b.  This effect is specific for the miRNA repressed by RRBP1 and do 
not globally alter miRNA expression since miR-29c was unaltered during these experiments.  
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We speculate that sequence homology may play a part in the co-upregulate since miR-200b 
and miR-200c rapidly upregulated one another within one hour inducing either but miR-200a 
and miR-141 upregulation was not increased until several hours later.  The same is true 
where induction of miR-200a rapidly upregulated miR-141 but miR-200b and miR-200c to a 
lesser extent.  Interestingly, miR-200b and miR-200c show the greatest sequence similarity to 
one another amongst the miR-200 family and miR-200a and miR-141 are also highly similar 
to each other and less to the family.  We found miR-429, having the more sequence 
divergence from any other miR-200 member, showed no detectable induction in any of the 
experiments.  From a biological standpoint it is understandable why a cell would devise such 
a mechanism of regulation since the miR-200 family function in parallel with one another to 
regulate stemness.  The miR-200 family often target the same mRNAs (e.g. ZEB1/2) but they 
can have individual effects on mRNAs regulating a particular process such as the regulation 
of miR-200c in the regulation of BMI1 (204).  Since these miRNAs are expressed from two 
different genomic clusters the cell upregulation of one cluster but not the other could cause 
faulty instructions to the cells as to whether or not to differentiate.  Therefore, maintaining a 
pool of pri-miRNA that can be post-transcriptionally upregulated in response to a single 
cluster being expressed would offer a buffer to this system.  It is possible RRBP1 functions 
as a repressor for other miRNA families in a similar mechanism and also that other 
undiscovered repressors function similarly for entirely different families of miRNAs.       
 The exact feedforward details were uncovered by utilizing an inducible system under 
highly stringent conditions to demonstrate for the first time miRNA species that regulate each 
other’s expression post-transcriptionally.  This observation led us to postulate the presence of 
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a yet undiscovered repressor complex, which we identified as the protein RRBP1.  To 
identify RRBP1, we developed a unique assay to capture short, non-polyadenylated, highly 
structured RNAs we call CLaPP.  The necessity of developing this assay stemmed from the 
need to overcome pitfalls of other similar approaches.  Castello and coworkers pioneered this 
technology to identify the in vivo complexes of RNA binding proteins on the entirety of the 
poly-(A)+ transcriptome; however, this method fails to identify RBPs on individual RNAs.  
Methods such as ChIRP and RAP added a level of specificity by using biotinylated antisense 
RNA oligos in a tiling array to capture the endogenous RNA species.  Yet these methods 
require long capture sequences (generally 150 nt) and fail to displace highly structured 
sequences, instead relying on redundancy in probes to capture the specific RNA.  When 
identifying proteins bound to precursor miRNAs these methods are incompatible because the 
precursors are shorter than the minimum capture probe length required and are almost 
entirely structured leaving no accessible areas for capture probe hybridization.  In using 
peptide nucleic acids we were able to overcome these shortcomings.  The use of our 
technique is applicable to identify RBPs bound to any RNA but is particularly useful for 
short, highly structured RNAs.  An additional benefit of the unique chemistry of PNAs comes 
with modifications to the PNAs allowing them to easily cross a cell membrane in the absence 
of a transfection reagent or delivery vehicle such as liposomes.  Conjugating a cell 
penetrating peptide sequence to the PNA allows them to readily cross the cell membrane in 
vitro and in vivo.  Future advances of the CLaPP technique described in this study could 
involve delivery of the PNA into live cells before crosslinking to allow hybridization to its 
target before cell lysis, thus reducing the degradation of the target mRNA following lysis but 
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before capture by the PNA.  A more exciting prospect lies in identifying protein-RNA 
complexes directly animals.  While the application of other methods to do this is technically 
feasible it becomes challenging when confronted with RNA degradation during extensive 
handling of tissues before RNA capture.  For example, to identify the proteins bound to 
mRNAs in particular tumors a tumor would need to be surgically extracted, dissociated to 
form a monolayer for crosslinking, and finally lysis before capture probes can be added.  
Using PNAs with cell penetrating peptides, one could simply inject the PNAs into the tumor 
mass to allow hybridization in vivo and depending on tumor size, can be directly crosslinked 
in the animal before extraction.  This technique could also be useful for identifying protein-
RNA interactions during the course of development in normal tissues.  For example, in utero 
injections of PNAs could identify key proteins interacting with RNAs during the 
development of the mouse embryo.  PNAs, not having a standard sugar phosphate backbone, 
are stable in the bloodstream since they are resistant to nucleases as well as proteases.  The 
only limitation to such a technique would be the necessity to rapidly recover the tissues since 
PNA-RNA interactions in a live cell can induce cleavage by the RNAi machinery so 
extended incubations would result in loss of the target rather than recovery.        
 We identified RRBP1 as inversely correlating to miR-200 expression by analyzing 
breast cancer cell lines as well as using genetic approaches for gain- and loss-of-function.  
Furthermore, we presented a complimentary mechanism by which TGF-β may regulate the 
miR-200 through upregulating RRBP1 expression.  Finally, we confirmed RRBP1 binds to 
precursor miR-200 members by conducting an iCLIP analysis.  Our proposed model of 
miR-200 regulation begins with RRBP1 upregulation by extracellular cues or ER stress 
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where it binds to the pre-miR-200 family members preventing their processing into the 
mature form.  This results in an epithelial-to-mesenchymal transition, an important 
developmental function of RRBP1, and the maintenance of stem-like characteristics.  This 
function is consistent with previous observations of RRBP1 function in both the induction of 
EMT in a chick embryo heart and elevated expression of RRBP1 in the stem cells residing in 
the colon (183, 205, 206).  Recently, a spliced form of the RNA for XBP1, a readout of 
endoplasmic reticulum stress, was found to correlate to basal-like breast cancer cells whereas 
luminal cells possessed no signed of ER stress (190).  Spliced XBP1 was found at increased 
levels in the stem cell population characterized as CD44high/CD24low suggesting a role in ER 
stress in maintaining a stem cell state.  We found RRBP1 expression closely follows this 
pattern in breast cancer cell lines in that basal-like cells possessed high levels of RRBP1.  
RRBP1 is a known regulator of ER stress by binding to GRP78 (also known as BiP) (207).  It 
will be interesting to uncover whether increased RRBP1 in breast stem cells is the cause or 
consequence of ER stress.  
 The endoplasmic reticulum plays a key role in protein secretion through its 
connection to the golgi apparatus that glycosylates proteins and ultimately releases them 
extracellularly through exocytosis.  Cells with specialized function for secretion often have 
an extended endoplasmic reticulum network to facilitate this process.  For example, B-cells, 
which secret large quantities of antibodies, have ER networks that take up nearly the entire 
volume of the cytoplasm (208).  Other such organs specialized for secretion include the 
pancreas and mammary glands.  The massive quantities of proteins produced and secreted by 
these cells inevitably induces an ER stress response leading to the activation of XBP1.  
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RRBP1 is a critical factor in protein section and its function in this process is conserved 
down through yeast (209, 210). If indeed RRBP1 and XBP1 expression is connected as seen 
in breast cancer cell lines, it may suggest that RRBP1 may also be important in the formation 
cancers in these cell types.  Furthermore, exosomes, lipid enclosed secretions from cells, 
have been found in elevated levels in cancers.  They may play a role in optimizing the ‘soil’ 
environment at the metastatic site in preparation for cancer cells to metastasize (211).  While 
the exact mechanisms responsible for exosome section are poorly characterized currently, it 
is possible that RRBP1 plays a role in this process given its known role in exocytosis.  
Additionally, metastatic cells often undergo an EMT before entering the circulatory system 
suggesting RRBP1 may regulate both the secretion of exosomes to prepare the metastatic site 
and inducing an EMT in the cells that are to metastasize.  
 It has become relatively accepted in the field that miRNA evolved as a primitive 
immune defense against viruses (212).  While plants and metazoans have similar biogenesis 
pathways, they share enough distinctions to suggest that miRNA evolved independently 
between plants and metazoans in an example of convergent evolution.  This study, as well as 
many others, has characterized multiple proteins involved in miRNA biogenesis as regulators 
of rRNA biogenesis.  We propose that in a necessity to defend themselves against viruses, 
early cells took advantage of the existing protein machinery for generating rRNA and 
redirected its purpose towards viral defense.  The cells that were able to do this survived viral 
infections and became generally more fit to their environment.  Over time cells repurposed 
RNAi against viruses and began finely tuning their own gene expression in what we currently 
recognize as miRNA.  Cells with more precise control of critical cellular functions such as 
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differentiation, apoptosis, cell cycle regulation, and more, provided a selective advantage 
over cells only able to defend against exogenous RNA.  We still have much to learn about 
miRNA biogenesis and future data may refute these claims; however, this seems a plausible 
explanation for the origin of miRNA biogenesis and the differences between animals and 
plants.    
5.2. Future studies
 In this study we identified a novel miRNA-media post-transcriptional feed forward 
loop between miRNA within closely related clusters.  This represents the first time such a 
loop has been characterized yet many other miRNA clusters exist with closely related 
miRNA (e.g. the miR-34a/b/c cluster).  This area is ripe for exploration.
 The development of the CLaPP assay was instrumental in identifying RRBP1 as a 
repressor of miRNA biogenesis.  The principles outlined in this study lay the groundwork for 
other studies where capturing a target RNA may prove troublesome by other techniques (i.e. 
highly structured RNAs, small RNAs, distinguishing RNAs from closely related 
homologues, etc…).  Furthermore, modification to the PNA allows them to easily cross the 
cell membrane, which opens the possibility to study protein-RNA interaction in animal 
models with a high degree of sensitivity and specificity.
 The functional role of RRBP1 has been understudied in the literature.  We 
characterized it as a key regulator in miRNA biogenesis.  It is possible that RRBP1 functions 
to regulate other miRNAs in a similar fashion.  Moreover, iCLIP sequencing data should 
reveal additional RNAs bound by RRBP1 that may serve to reinforce the phenotypes 
associated with miR-200 expression to generate an RRBP1 ‘signature’.  The fate of the 
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precursor miRNA bound by RRBP1 still remains unclear.  It is possible they persist for long 
periods of time but it is equally likely that they get funneled into a degradation pathway to 
maintain constant levels similar to let-7 following uridylation.         
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Appendix
Table A1:Top differentially expressed miRNA between ZEB1/2 low and high breast 
cancers
miRNA logFC AveExpr t P.Value adj.P.Val B
hsa-mir-21 0.447 17.718 5.799 1.71E-08 2.42E-07 8.762
hsa-mir-22 0.435 16.115 7.014 1.58E-11 4.46E-10 15.564
hsa-mir-10b 0.909 15.981 9.817 7.13E-20 5.33E-18 34.425
hsa-mir-148a -0.512 15.453 -4.122 4.89E-05 0.0003758 1.127
hsa-mir-143 0.741 15.209 7.154 6.67E-12 2.12E-10 16.405
hsa-mir-183 -0.611 13.739 -4.818 2.32E-06 2.21E-05 4.029
hsa-mir-200c -0.774 13.241 -7.944 4.13E-14 1.73E-12 21.384
hsa-mir-25 -0.322 12.977 -3.875 0.0001313 0.0009475 0.194
hsa-mir-92a-2 -0.601 12.728 -5.527 7.15E-08 9.46E-07 7.380
hsa-mir-199b 1.041 12.098 9.743 1.24E-19 8.64E-18 33.881
hsa-mir-93 -0.689 11.878 -6.908 3.03E-11 8.12E-10 14.929
hsa-mir-199a-2 1.074 11.749 10.370 1.09E-21 1.14E-19 38.547
hsa-mir-100 1.141 11.458 10.025 1.50E-20 1.31E-18 35.961
hsa-let-7c 1.189 11.055 9.525 6.25E-19 3.63E-17 32.288
hsa-mir-199a-1 1.102 10.988 10.830 3.07E-23 4.01E-21 42.063
hsa-mir-141 -0.952 10.597 -8.609 4.47E-16 2.12E-14 25.826
hsa-mir-1307 -0.706 10.280 -5.836 1.40E-08 2.07E-07 8.954
hsa-mir-145 0.618 10.249 5.243 3.02E-07 3.51E-06 5.989
hsa-mir-191 -0.553 9.840 -4.397 1.54E-05 0.0001295 2.225
hsa-mir-127 1.273 9.714 12.670 1.13E-29 5.89E-27 56.682
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hsa-mir-200a -0.534 9.658 -4.029 7.14E-05 0.00053 0.768
hsa-mir-125b-1 0.977 9.558 9.058 1.87E-17 9.77E-16 28.946
hsa-mir-99a 1.270 9.385 9.961 2.42E-20 1.95E-18 35.489
hsa-mir-379 1.521 9.246 13.418 2.22E-32 2.32E-29 62.832
hsa-mir-140 0.485 9.121 5.220 3.37E-07 3.88E-06 5.883
hsa-mir-150 1.103 9.091 4.896 1.61E-06 1.59E-05 4.377
hsa-mir-16-1 -0.470 9.067 -5.167 4.40E-07 4.69E-06 5.628
hsa-mir-106b -0.577 9.033 -5.824 1.50E-08 2.17E-07 8.893
hsa-mir-200b -0.643 9.008 -4.922 1.43E-06 1.44E-05 4.496
hsa-mir-17 -0.897 8.790 -7.068 1.14E-11 3.31E-10 15.883
hsa-mir-192 -0.633 8.713 -5.428 1.19E-07 1.53E-06 6.888
hsa-mir-9-1 -1.309 8.679 -5.214 3.49E-07 3.96E-06 5.851
hsa-mir-9-2 -1.327 8.667 -5.268 2.66E-07 3.20E-06 6.111
hsa-mir-134 1.161 8.572 11.122 3.10E-24 5.40E-22 44.324
hsa-mir-30b -0.540 8.548 -4.331 2.04E-05 0.0001665 1.956
hsa-mir-210 -1.522 8.498 -6.302 1.07E-09 1.96E-08 11.458
hsa-mir-92a-1 -0.759 8.426 -6.115 3.06E-09 5.08E-08 10.434
hsa-mir-29b-2 -0.542 8.230 -4.645 5.12E-06 4.66E-05 3.272
hsa-mir-186 -0.441 8.093 -4.134 4.65E-05 0.00036 1.174
hsa-mir-152 0.630 7.980 7.192 5.28E-12 1.73E-10 16.634
hsa-mir-29b-1 -0.565 7.949 -4.697 4.04E-06 3.74E-05 3.498
hsa-mir-338 -0.543 7.800 -4.010 7.70E-05 0.0005675 0.697
hsa-mir-542 0.729 7.707 6.179 2.14E-09 3.66E-08 10.782
hsa-mir-148b -0.493 7.515 -6.077 3.77E-09 6.17E-08 10.229
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hsa-mir-423 -0.431 7.220 -5.209 3.56E-07 4.00E-06 5.831
hsa-mir-20a -0.825 7.160 -6.620 1.69E-10 3.76E-09 13.253
hsa-mir-708 0.685 6.827 6.521 3.02E-10 6.38E-09 12.685
hsa-mir-15a -0.308 6.807 -4.043 6.75E-05 0.0005079 0.822
hsa-mir-19b-2 -0.834 6.532 -6.121 2.96E-09 4.99E-08 10.467
hsa-mir-484 -0.566 6.490 -5.098 6.14E-07 6.37E-06 5.305
hsa-mir-429 -0.899 6.323 -5.260 2.77E-07 3.29E-06 6.071
hsa-mir-98 -0.376 5.810 -3.977 8.78E-05 0.0006421 0.573
hsa-mir-339 -0.563 5.697 -5.186 4.00E-07 4.36E-06 5.718
hsa-mir-328 -0.677 5.564 -4.913 1.49E-06 1.49E-05 4.454
hsa-mir-324 -0.814 5.455 -7.277 3.10E-12 1.08E-10 17.155
hsa-mir-744 -0.807 5.420 -6.693 1.10E-10 2.62E-09 13.670
hsa-mir-331 -0.488 5.303 -4.272 2.62E-05 0.0002057 1.719
hsa-mir-139 0.747 5.261 5.801 1.70E-08 2.42E-07 8.771
hsa-mir-505 -0.613 5.136 -4.369 1.73E-05 0.0001438 2.111
hsa-mir-136 0.803 5.124 6.467 4.12E-10 8.29E-09 12.383
hsa-mir-409 1.114 5.087 10.260 2.53E-21 2.40E-19 37.715
hsa-mir-337 1.374 5.068 9.680 1.99E-19 1.30E-17 33.416
hsa-mir-218-2 0.736 4.992 7.114 8.55E-12 2.63E-10 16.164
hsa-mir-214 1.134 4.971 9.354 2.19E-18 1.21E-16 31.054
hsa-mir-96 -1.021 4.803 -5.608 4.69E-08 6.29E-07 7.787
hsa-mir-769 -0.497 4.769 -5.940 8.00E-09 1.27E-07 9.500
hsa-mir-32 -0.502 4.679 -4.567 7.28E-06 6.51E-05 2.936
hsa-mir-382 1.259 4.487 11.855 8.82E-27 2.31E-24 50.105
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hsa-mir-381 1.276 4.484 10.904 1.72E-23 2.57E-21 42.631
hsa-mir-130b -0.631 4.433 -4.975 1.11E-06 1.14E-05 4.739
hsa-mir-181d -0.556 4.246 -4.316 2.17E-05 0.0001731 1.898
hsa-mir-1247 1.398 4.228 6.519 3.05E-10 6.38E-09 12.675
hsa-mir-345 -0.846 4.214 -5.199 3.75E-07 4.13E-06 5.781
hsa-mir-654 1.274 4.153 9.671 2.12E-19 1.30E-17 33.353
hsa-mir-125b-2 1.112 4.073 8.381 2.17E-15 9.86E-14 24.275
hsa-mir-758 1.538 4.041 12.434 7.84E-29 2.73E-26 54.767
hsa-mir-450b 0.513 4.025 4.302 2.30E-05 0.0001823 1.841
hsa-mir-19a -0.996 3.977 -6.459 4.34E-10 8.56E-09 12.333
hsa-mir-590 -0.873 3.932 -5.203 3.67E-07 4.08E-06 5.802
hsa-mir-1301 -0.796 3.777 -5.946 7.74E-09 1.25E-07 9.532
hsa-mir-33a -1.191 3.729 -5.933 8.31E-09 1.30E-07 9.464
hsa-mir-1180 -0.862 3.562 -5.874 1.15E-08 1.71E-07 9.152
hsa-mir-493 1.170 3.511 7.008 1.64E-11 4.51E-10 15.528
hsa-mir-301a -1.199 3.501 -5.740 2.34E-08 3.22E-07 8.459
hsa-mir-3074 -0.674 3.491 -4.369 1.73E-05 0.0001438 2.111
hsa-mir-370 1.297 3.188 11.695 3.21E-26 6.71E-24 48.832
hsa-mir-1306 -0.647 3.173 -4.675 4.48E-06 4.11E-05 3.400
hsa-mir-34c 0.744 3.152 4.754 3.12E-06 2.94E-05 3.748
hsa-mir-431 1.315 3.134 10.806 3.71E-23 4.31E-21 41.875
hsa-mir-454 -0.798 3.127 -5.768 2.02E-08 2.82E-07 8.601
hsa-mir-103-2 -0.554 3.111 -5.142 4.97E-07 5.25E-06 5.511
hsa-mir-671 -0.626 3.092 -6.362 7.58E-10 1.42E-08 11.789
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hsa-mir-889 1.289 2.955 6.400 6.08E-10 1.16E-08 12.005
hsa-mir-362 -0.649 2.929 -4.937 1.33E-06 1.35E-05 4.563
hsa-mir-369 1.161 2.927 7.098 9.42E-12 2.82E-10 16.069
hsa-mir-539 0.958 2.915 4.032 7.05E-05 0.0005268 0.780
hsa-mir-16-2 -0.824 2.907 -5.169 4.33E-07 4.67E-06 5.641
hsa-mir-18a -1.137 2.667 -5.495 8.45E-08 1.10E-06 7.218
hsa-mir-154 1.164 2.568 7.358 1.86E-12 6.71E-11 17.655
hsa-mir-184 2.249 2.507 4.362 1.78E-05 0.0001466 2.084
hsa-mir-19b-1 -0.772 2.388 -4.443 1.25E-05 0.0001084 2.418
hsa-mir-410 1.916 2.357 6.768 7.02E-11 1.79E-09 14.107
hsa-mir-495 1.406 2.258 7.403 1.40E-12 5.23E-11 17.933
hsa-mir-411 1.918 2.214 8.053 2.01E-14 8.75E-13 22.091
hsa-mir-432 1.631 2.205 8.677 2.77E-16 1.38E-14 26.296
hsa-mir-33b -1.589 2.202 -5.098 6.15E-07 6.37E-06 5.304
hsa-mir-940 -1.094 1.912 -3.964 9.26E-05 0.0006727 0.523
hsa-mir-487b 1.810 1.808 7.448 1.05E-12 4.07E-11 18.213
hsa-mir-376c 1.118 1.665 4.590 6.55E-06 5.91E-05 3.037
hsa-mir-483 2.016 1.645 5.417 1.26E-07 1.57E-06 6.834
hsa-mir-485 1.706 1.641 6.577 2.18E-10 4.74E-09 13.005
hsa-mir-412 2.142 1.423 6.297 1.10E-09 1.98E-08 11.431
hsa-mir-323 1.436 1.214 4.697 4.05E-06 3.74E-05 3.498
hsa-mir-377 1.686 1.120 6.622 1.67E-10 3.76E-09 13.260
hsa-mir-299 1.836 1.117 6.728 8.91E-11 2.17E-09 13.876
hsa-mir-760 -1.465 1.046 -4.523 8.82E-06 7.69E-05 2.753
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hsa-mir-1245 2.185 0.953 7.197 5.11E-12 1.72E-10 16.666
hsa-mir-496 2.109 0.466 6.426 5.25E-10 1.02E-08 12.148
hsa-mir-655 2.460 -0.010 5.906 9.65E-09 1.48E-07 9.318
hsa-mir-3926-1 2.011 -0.291 5.427 1.20E-07 1.53E-06 6.882
hsa-mir-487a 2.741 -0.663 6.285 1.18E-09 2.08E-08 11.363
hsa-mir-204 3.660 -0.687 6.511 3.20E-10 6.56E-09 12.629
hsa-mir-1277 -2.162 -0.983 -4.536 8.36E-06 7.35E-05 2.804
hsa-mir-543 3.333 -0.983 7.813 9.83E-14 3.95E-12 20.534
hsa-mir-376b 2.191 -1.035 4.545 8.02E-06 7.11E-05 2.843
hsa-mir-494 2.724 -1.040 5.344 1.82E-07 2.21E-06 6.478
hsa-mir-218-1 2.648 -1.798 4.879 1.74E-06 1.70E-05 4.305
hsa-mir-1295 2.785 -1.871 5.422 1.23E-07 1.55E-06 6.857
hsa-mir-433 3.051 -1.878 5.710 2.75E-08 3.73E-07 8.304
hsa-mir-1258 4.038 -2.458 6.778 6.61E-11 1.73E-09 14.166
hsa-mir-656 2.299 -2.856 4.070 6.04E-05 0.0004574 0.927
hsa-mir-380 3.444 -3.077 5.898 1.01E-08 1.53E-07 9.277
hsa-mir-3129 2.616 -3.682 4.322 2.12E-05 0.0001716 1.920
hsa-mir-1262 2.748 -3.745 4.404 1.49E-05 0.0001265 2.255
hsa-mir-202 3.583 -3.746 5.361 1.67E-07 2.05E-06 6.562
hsa-mir-541 4.149 -4.333 6.679 1.19E-10 2.78E-09 13.589
hsa-mir-665 3.923 -4.586 6.214 1.75E-09 3.05E-08 10.976
hsa-mir-376a-2 3.105 -4.669 4.817 2.33E-06 2.21E-05 4.027
hsa-mir-605 2.668 -4.781 4.107 5.20E-05 0.0003974 1.067
hsa-mir-329-2 3.343 -4.920 5.258 2.80E-07 3.29E-06 6.063
141
hsa-mir-329-1 3.122 -5.293 4.853 1.97E-06 1.91E-05 4.187
hsa-mir-1185-1 4.247 -5.900 6.745 8.04E-11 2.00E-09 13.976
hsa-mir-3926-2 2.902 -6.194 4.427 1.35E-05 0.0001156 2.349
hsa-mir-346 2.616 -8.355 4.218 3.29E-05 0.0002566 1.502
hsa-mir-1185-2 2.621 -8.501 4.318 2.15E-05 0.0001731 1.903
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